1
|
Tutino R, Bonomi A, Zingaretti CC, Risi L, Ragaini EM, Viganò L, Paterno M, Pezzoli I. Locally advanced mid/low rectal cancer with synchronous resectable liver metastases: systematic review of the available strategies and outcome. Updates Surg 2024; 76:345-361. [PMID: 38182850 DOI: 10.1007/s13304-023-01735-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2023] [Accepted: 12/12/2023] [Indexed: 01/07/2024]
Abstract
The management of patients with locally advanced mid/low rectal cancer with resectable liver metastases is complex because of the need to combine the optimal treatment of both tumors. This study aims to review the available treatment strategies and compare their outcome, focusing on radiotherapy (RT) and liver-first approach (LFA). A systematic review was performed in PubMed, Embase, and web sources including articles published between 2000 and 02/2023 and reporting mid-/long-term outcomes. Overall, twenty studies were included (n = 1837 patients). Three- and 5-year overall survival (OS) rates were 51-88% and 36-59%. Although several strategies were reported, most patients received RT (1448/1837, 79%; > 85% neoadjuvant). RT reduced the pelvic recurrence risk (5.8 vs. 13.5%, P = 0.005) but did not impact OS. Six studies analyzed LFA (n = 307 patients). LFA had a completion rate similar to the rectum-first approach (RFA, 81% vs. 79%) but the interval strategy-an LFA variant with liver surgery in the interval between radiotherapy and rectal surgery-had a better completion rate than standard LFA (liver surgery/radiotherapy/rectal surgery, 92% vs. 75%, P = 0.011) and RFA (79%, P = 0.048). Across all series, LFA achieved the best survival rates, and in one paper it led to a survival advantage in patients with multiple metastases. In conclusion, different strategies can be adopted, but RT should be included to decrease the pelvic recurrence risk. LFA should be considered, especially in patients with high hepatic tumor burden, and RT before liver surgery (interval strategy) could maximize its completion rate.
Collapse
Affiliation(s)
- R Tutino
- Department of General and Emergency Surgery, AOU Città della Salute e della Scienza di Torino, Turin, Italy
| | - A Bonomi
- Department of General Surgery, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, Milan, Italy
- General Surgery Residency Program, University of Milan, Milan, Italy
| | - C C Zingaretti
- Department of Digestive and Hepatobiliary Surgery, Mauriziano Umberto I Hospital, Turin, Italy
| | - L Risi
- Department of Biomedical Sciences, Humanitas University, Viale Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy
- Hepatobiliary Unit, Department of Minimally Invasive General and Oncologic Surgery, Humanitas Gavazzeni University Hospital, Viale M. Gavazzeni 21, 24125, Bergamo, Italy
| | - E M Ragaini
- Department of Biomedical Sciences, Humanitas University, Viale Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy
| | - L Viganò
- Department of Biomedical Sciences, Humanitas University, Viale Rita Levi Montalcini 4, Pieve Emanuele, 20090, Milan, Italy.
- Hepatobiliary Unit, Department of Minimally Invasive General and Oncologic Surgery, Humanitas Gavazzeni University Hospital, Viale M. Gavazzeni 21, 24125, Bergamo, Italy.
| | - M Paterno
- General Surgery Residency Program, University of Milan, Milan, Italy
- Division of Oncologic and Minimally Invasive Surgery, Niguarda General Hospital, Milan, Italy
| | - I Pezzoli
- General Surgery Residency Program, University of Milan, Milan, Italy
| |
Collapse
|
2
|
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J. The Functional Assessment of Cancer Therapy Scale: Development and Validation of the General Measure. J Clin Oncol 2023; 41:5335-5344. [PMID: 38056080 DOI: 10.1200/jco.22.02775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/08/2023] Open
Abstract
PURPOSE We developed and validated a brief, yet sensitive, 33-item general cancer quality-of-life (QL) measure for evaluating patients receiving cancer treatment, called the Functional Assessment of Cancer Therapy (FACT) scale. METHODS AND RESULTS The five-phase validation process involved 854 patients with cancer and 15 oncology specialists. The initial pool of 370 overlapping items for breast, lung, and colorectal cancer was generated by open-ended interview with patients experienced with the symptoms of cancer and oncology professionals. Using preselected criteria, items were reduced to a 38-item general version. Factor and scaling analyses of these 38 items on 545 patients with mixed cancer diagnoses resulted in the 28-item FACT-general (FACT-G, version 2). In addition to a total score, this version produces subscale scores for physical, functional, social, and emotional well-being, as well as satisfaction with the treatment relationship. Coefficients of reliability and validity were uniformly high. The scale's ability to discriminate patients on the basis of stage of disease, performance status rating (PSR), and hospitalization status supports its sensitivity. It has also demonstrated sensitivity to change over time. Finally, the validity of measuring separate areas, or dimensions, of QL was supported by the differential responsiveness of subscales when applied to groups known to differ along the dimensions of physical, functional, social, and emotional well-being. CONCLUSION The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change. Selecting it for a clinical trial adds the capability to assess the relative weight of various aspects of QL from the patient's perspective.
Collapse
|
3
|
Camera M, Brambilla M, Canzano P, Becchetti A, Conti M, Agostoni PG, Pengo M, Tortorici E, Mancini ME, Andreini D, Bonomi A, Parati GF. Long COVID-19 syndrome: association of cardiopulmonary impairment with a persistent platelet activation. Eur Heart J 2022. [PMCID: PMC9619691 DOI: 10.1093/eurheartj/ehac544.3038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Background A considerable proportion of patients do not fully recover from COVID-19 infection and report symptoms that persist beyond the initial phase of infection: this condition is defined long-COVID-19 syndrome (LCS). LCS can involve lungs as well as several extrapulmonary organs, including the cardiovascular system. The risk and 1-year burden of cardiovascular diseases (CVD) is increased in COVID-19 survivors, even in subjects at low risk of CVD. Recently, we documented that acute COVID-19 infection induces altered platelet activation state characterized by a prothrombotic phenotype and by the formation of platelet-leukocyte aggregates (PLA), that may be involved in the pulmonary microthrombi found in autoptic specimens. No data are yet available on the contribution of platelet activation to residual pulmonary impairment and procoagulant potential in LCS patients. Purpose To study platelet activation status, microvesicle (MV) profile, platelet thrombin generation capacity (pTGC) in LCS patients enrolled at 6 months after resolution of the acute phase (6mo-FU), compared to acute COVID-19 infection patients. Methods 6mo-FU COVID-19 patients (n=24) with established LCS were enrolled at Centro Cardiologico Monzino. Residual pulmonary impairment was assessed by Cardiopulmonary Exercise Testing (CPET) and 64-rows-CT scan evaluation. Platelet activation (P-selectin, Tissue Factor [TF] and PLA) and MV profile were assessed by flow cytometry; pTGC by calibrated automated thrombogram. 46 patients enrolled during acute COVID-19 infection and 46 healthy subjects (HS) were used for comparison. Results Dispnea in LCS patients was confirmed by CPET showing compromised alveolus-capillary membrane diffusion and residual pulmonary impairment. TF+-platelet and -MV levels were 3-fold (1.5% [1.2–2.9] vs 2.4% [1.6–5.7]) and 2-fold (217/μl [137–275] vs 435/μl [275–633]) lower at 6mo-FU compared to acute phase, being comparable to HS. pTGC behaved similarly. At 6mo-FU, the MV profile, in terms of total number and cell origin, returned to physiological levels. Conversely, although lower than that measured in acute phase, a 2.5-fold higher platelet P-selectin expression (6.9% [3–13.5] vs 11.7% [5.2–18.9]) and PLA formation (35.5% [27.4–46.8] vs 67.7% [45.7–85.3]) was observed at 6mo-FU compared to HS. Interestingly, a significant correlation between PLA formation and residual pulmonary impairment was observed (r=−0.423; p=0.02). Conclusion These data strengthen the hypothesis that the presence of PLA in the bloodstream, and thus also in the pulmonary microcirculation, may contribute to support pulmonary dysfunction still observed in LCS patients. Funding Acknowledgement Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Italian Ministry of Health (Ricerca Corrente 2020 MPP COVID4)
Collapse
Affiliation(s)
- M Camera
- University of Milan, eDepartment of Pharmaceutical Sciences , Milan , Italy
| | | | - P Canzano
- Centro cardiologico Monzino , Milan , Italy
| | | | - M Conti
- Centro cardiologico Monzino , Milan , Italy
| | | | - M Pengo
- Italian Auxological Institute San Luca Hospital , Milan , Italy
| | - E Tortorici
- Italian Auxological Institute San Luca Hospital , Milan , Italy
| | | | - D Andreini
- Centro cardiologico Monzino , Milan , Italy
| | - A Bonomi
- Centro cardiologico Monzino , Milan , Italy
| | - G F Parati
- Italian Auxological Institute San Luca Hospital , Milan , Italy
| |
Collapse
|
4
|
Lo Russo G, Agostoni PG, Campodonico J, Junod D, Carulli E, Gaudenzi Asinelli M, Doni F, Bonomi A. Role of impaired iron transport on exercise performance in heart failure patients. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aims
Impaired iron transport (IIT) occurs frequently in heart failure (HF) patients, even in the absence of anaemia and it is associated with a poor quality of life and prognosis. The impact of IIT on exercise capacity, as assessed by the cardiopulmonary exercise test (CPET), in HF is at present unknown. The aim of this article is to evaluate in HF patients the impact on exercise performance of IIT, defined as transferrin saturation (TSAT) <20%.
Methods and results
We collected data of 676 patients hospitalised for HF. All underwent laboratory analysis, cardiac ultrasound, and CPET. Patients were grouped by the presence/absence of IIT and anaemia (haemoglobin <13 and <12 g/dL in male and female, respectively): Group 1 (G1) no anaemia, no IIT; Group 2 (G2) anaemia, no IIT; Group 3 (G3) no anaemia, IIT; Group 4 (G4) anaemia and IIT. Peak oxygen uptake (peakVO2) reduced from G1 to G3 and from G2 to G4 (G1: 1266±497 mL/min, G2: 1011±385 mL/min, G3: 1041±395 mL/min, G4: 833±241 mL/min), whereas the ventilation to carbon dioxide relationship slope (VE/VCO2 slope) increased (G1: 31.8±7.5, G2: 34.5±7.4, G3: 36.1±10.2, G4: 37.5±8.4). At multivariate regression analysis, peakVO2 independent predictors were anaemia, brain natriuretic peptide (BNP), and left ventricular ejection fraction, whereas VE/VCO2 slope independent predictors were IIT and BNP.
Conclusions
In HF IIT is associated with exercise performance impairment independently from anaemia, and it is a predictor of elevated VE/VCO2 slope, a pivotal index of HF prognosis.
Funding Acknowledgement
Type of funding sources: Private hospital(s). Main funding source(s): Centro cardiologico Monzino, Italy
Collapse
Affiliation(s)
- G Lo Russo
- IRCCS Monzino Cardiology Center , Milan , Italy
| | | | | | - D Junod
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - E Carulli
- IRCCS Monzino Cardiology Center , Milan , Italy
| | | | - F Doni
- IRCCS Monzino Cardiology Center , Milan , Italy
| | - A Bonomi
- IRCCS Monzino Cardiology Center , Milan , Italy
| |
Collapse
|
5
|
Trombara F, Cosentino N, Genovese S, Bonomi A, Ludergnani M, Poggio P, Agostoni PG, Marenzi G. Impact of chronic GLP-1 receptor agonist and SGLT-2 inhibitor therapy on in-hospital outcomes of patients with diabetes mellitus hospitalized with acute myocardial infarction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection in addition to their glucose-lowering effect. Whether their benefits occur also in patients with diabetes mellitus (DM) during hospitalisation with acute myocardial infarction (AMI) has not been investigated yet.
Purpose
We evaluated in-hospital outcomes of patients hospitalised with AMI according to their chronic use (before hospitalisation) of GLP-1 RA and SGLT-2i therapy.
Methods
Using administrative healthcare databases, we analysed patients hospitalised with a primary diagnosis of AMI from 2010 to 2019 in the Lombardy region, Italy. Patients were stratified according to their DM status, then divided into three cohorts: Group 1 (non-DM patients); Group 2 (DM patients taking GLP-1 RA or SGLT-2i); and Group 3 (DM patients not taking GLP-1 RA and/or SGLT-2i). Patients were matched in a 1:1:1 ratio using a propensity score including all available variables. The primary endpoint of the study was the composite of in-hospital mortality, acute heart failure, and acute kidney injury requiring renal replacement therapy.
Results
We identified 146,800 patients hospitalised with AMI (26% of them with DM). After propensity score matching, 1,030 patients were included in each group. The primary endpoint rate in the overall population was 16% (n=502) and it significantly increased going from Group 1 to Group 3 (13%, 16%, and 20% respectively; p for trend <0.0001). The risk of the composite endpoint significantly increased from Group 1 to Group 3 (P for trend <0.0001). In comparison with Group 2, Group 3 had a significant higher risk of the composite endpoint (OR 1.40 [95% CI 1.11–1.77]).
Conclusions
Our study shows that DM patients hospitalised with AMI and on chronic GLP-1 RA and/or SGLT-2i therapy have a better in-hospital clinical outcome than DM patients without them.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- F Trombara
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - N Cosentino
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - S Genovese
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - A Bonomi
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - M Ludergnani
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - P Poggio
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - P G Agostoni
- Monzino Cardiology Center, IRCCS , Milan , Italy
| | - G Marenzi
- Monzino Cardiology Center, IRCCS , Milan , Italy
| |
Collapse
|
6
|
Bergonti M, Spera F, Tijskens M, Bonomi A, Saenen J, Huybrechts W, Miljoen H, Wittock A, Casella M, Tondo C, Heidbuchel H, Sarkozy A. A new prediction model for left ventricular systolic function recovery after catheter ablation of atrial fibrillation in patients with heart failure and reduced ejection fraction, The ANTWOORD Study. Europace 2022. [DOI: 10.1093/europace/euac053.185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
In patients with heart failure with reduced ejection fraction (HFrEF) and atrial fibrillation (AF), pulmonary vein isolation (PVI) improves left ventricular ejection fraction (LVEF), along with prognosis, in a variable percentage of patients.
Aim
To investigate the predictors of LVEF recovery after PVI and to develop a prediction model for individualized assessment.
Methods
We conducted an observational, retrospective, single-center study on 111 consecutive patients with AF and HFrEF undergoing PVI. Patients were divided into Responder vs. Non-Responder according to the "Universal definition of HF". Clinical predictors were evaluated by multivariate logistic regression analysis and cross-validation technique. Independent predictors were used to build an internally validated prediction model.
Results Responders (54%) had significantly shorter QRS duration and less dilated left atria. Persistent AF and absence of a known etiology more frequent among Responders. AF recurrence was non-significantly different between the two groups (p=0.2), although clinical AF burden was lower in Responders, after PVI (p<0.001). Absence of known etiology, presence of persistent AF, left atrial volume index<50ml/m2, and QRS<120msec were independent predictors of LVEF recovery and composed the "Antwerp Score". Patients with Antwerp Score ≤1 had 90% likelihood of LVEF recovery, compared to 5% in patients with 3-6.
Conclusions Patients with wide QRS complex, known HF etiology, dilated left atria, and paroxysmal AF were less likely to recover LVEF after PVI. A new score system based on the above-mentioned parameters adequately predict LV function recovery after PVI. These results warrant confirmation and prospective validation.
Collapse
Affiliation(s)
- M Bergonti
- University Hospital Antwerp, Antwerpen, Belgium
| | - F Spera
- University Hospital Antwerp, Antwerpen, Belgium
| | - M Tijskens
- University Hospital Antwerp, Antwerpen, Belgium
| | - A Bonomi
- Monzino Cardiology Center, IRCCS, Heart Rhythm Center, Milan, Italy
| | - J Saenen
- University Hospital Antwerp, Antwerpen, Belgium
| | | | - H Miljoen
- University Hospital Antwerp, Antwerpen, Belgium
| | - A Wittock
- University Hospital Antwerp, Antwerpen, Belgium
| | - M Casella
- Marche Polytechnic University of Ancona, Clinica di Cardiologia e Aritmologia, Dipartimento di Scienze Biomediche e Sanità Pubblica, Ancona, Italy
| | - C Tondo
- Monzino Cardiology Center, IRCCS, Heart Rhythm Center, Milan, Italy
| | | | - A Sarkozy
- University Hospital Antwerp, Antwerpen, Belgium
| |
Collapse
|
7
|
Mapelli M, Salvioni E, Paneroni M, Gugliandolo P, Bonomi A, Scalvini S, Raimondo R, Sciomer S, Mattavelli I, La Rovere M, Agostoni P. P244 BRISK WALKING CAN BE A MAXIMAL EFFORT IN HEART FAILURE PATIENTS. A COMPARISON OF CARDIOPULMONARY EXERCISE AND SIX–MINUTE WALKING TEST CARDIORESPIRATORY DATA. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Aims
Cardiopulmonary exercise test (CPET) and six–minute walking test (6MWT) are frequently used in heart failure (HF). CPET is a maximal exercise, whereas 6MWT is a self–selected constant load test usually considered a submaximal, and therefore safer, exercise but this has not been tested previously. The aim of this study was to compare the cardiorespiratory parameters collected during CPET and 6MWT in a large group of healthy subjects and patients with HF of different severity.
Methods and Results
Subjects performed a standard maximal CPET and a 6MWT wearing a portable device allowing breath–by–breath measurement of cardiorespiratory parameters. HF Patients were grouped according to their CPET peak oxygen uptake (peakV̇O2). One–hundred and fifty–five subjects were enrolled, of whom 40 were healthy (59±8 years; male 67%) and 115 were HF patients (69±10 years; male 80%; left ventricular ejection fraction 34.6±12.0%). CPET peakV̇O2 was 13.5±3.5 ml/kg/min in HF patients and 28.1±7.4 ml/kg/min in healthy (p < 0.001). 6MWT–V̇O2 was 98±20% of the CPET peakV̇O2 values in HF patients, while 72±20% in healthy subjects (p < 0.001). 6MWT–V̇O2 was >110% of CPET peakV̇O2 in 42% of more severe HF patients (peakV̇O2<12ml/kg/min). Similar results have been found for ventilation and heart rate. Of note, the slope of the relationship between V̇O2 at 6MWT, reported as percentage of CPET peakV̇O2 vs. 6MWT V̇O2 reported as absolute value, progressively increased as exercise limitation did.
Conclusions
6MWT must be perceived as a maximal or even supra–maximal exercise activity at least in patients with severe exercise limitation from HF. Our findings should influence the safety procedures needed for the 6MWT in HF.
Collapse
Affiliation(s)
- M Mapelli
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - E Salvioni
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - M Paneroni
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - P Gugliandolo
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - A Bonomi
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - S Scalvini
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - R Raimondo
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - S Sciomer
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - I Mattavelli
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - M La Rovere
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| | - P Agostoni
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, LUMEZZANE BRESCIA; RESPIRATORY REHABILITATION, ISTITUTI CLINICI SCIENTIFICI MAUGERI, IRCCS, TRADATE, VARESE, ITALY, TRADATE; DIPARTIMENTO DI SCIENZE CARDIOVASCOLARI, RESPIRATORIE, NEFROLOGICHE, ANESTESIOLOGICHE E GERIATRICHE, “SAPIENZA”, ROMA; DEPARTMENT OF CARDIAC REHABILITATION,
| |
Collapse
|
8
|
Elisabetta S, Mapelli M, Bonomi A, Mattavelli I, De Martino F, Vignati C, Gugliandolo P, Agostoni P. C73 PICK YOUR THRESHOLD! HOW TO CALCULATE THE ANAEROBIC THRESHOLD TO STRATIFY HEART FAILURE PROGNOSIS: A COMPARISON BETWEEN ABSOLUTE VALUE, PERCENTAGE OF PEAK VO2 OR PERCENTAGE OF PREDICTED MAXIMUM VO2 IN A LARGE MULTICENTER COHORT OF HFREF PATIENTS WHO UNDER. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac011.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Background
The anaerobic threshold (AT), identifies the moment during a maximal exercise when hyperventilation occurs in response to the introduction of an anaerobic metabolism. Its value is indicative of the subject‘s training and/or health, it can be used to guide training, rehabilitation or to define appropriateness to undergo major thoracic or abdominal surgery, and it is related to heart failure (HF) prognosis. AT can be expressed as absolute value or as the percentage of predicted maximum VO2 (VO2AT%pred). However, it is not uncommon to find papers that refer AT to the peak VO2 value achieved (VO2AT%peak), rather than its predicted value, but a direct comparison of the prognostic power of these different variables is missing. In this work, we aim to compare the risk–identifying ability of the AT value when expressed in these three different ways in a large population of HF patients. This will help identify which is more correct to use in assessing patient prognosis, especially when peakVO2 is not reached appropriately.
Methods
The population analyzed counts 7746 patients with HF with history of reduced EF (<40%), recruited between 1998 and 2020 within the MECKI score project. All patients underwent a maximal cardiopulmonary exercise test (CPET), executed in using a ramp protocol on an electronically braked cycle ergometer.
Results
The present study considered 6157 HF patients with identified AT during the CPET, with a median follow up of 1528 days (689–1826). The main characteristics are reported in Figure 1. Figure 2 shows stratification of patients according to these 3 variables divided in tertiles, considering cardiovascular death (combination of cardiovascular death, urgent transplant or LVAD implantation) as an end point. Comparing the AUC of the three variables considered, we found similar values between VO2AT and VO2AT%pred, while the peak VO2AT% value was significantly lower (p < 0.001), as shown in Figure 3A. Moreover VO2AT%pred is the only variable to maintain a comparable ROC to the peakVO2 one, with the others being significantly lower (Figure 3B).
Conclusions
VO2 at AT should always be expressed as % of predicted maximal VO2 to be reliable in predicting prognosis in HF patients. Moreover, evaluating a sub–maximal exercise, VO2AT%pred is the only variable to maintain a comparable prognostic power to the peakVO2 one.
Collapse
Affiliation(s)
- S Elisabetta
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | - M Mapelli
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | - A Bonomi
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | - I Mattavelli
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | - F De Martino
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | - C Vignati
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| | | | - P Agostoni
- CENTRO CARDIOLOGICO MONZINO, IRCCS, MILANO, MILANO
| |
Collapse
|
9
|
Pezzuto B, Badagliacca R, Muratori M, Farina S, Bussotti M, Correale M, Bonomi A, Vignati C, Sciomer S, Papa S, Palazzo Adriano E, Agostoni P. ROLE OF CARDIOPULMONARY EXERCISE TEST IN THE PREDICTION OF HEMODYNAMIC IMPAIRMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Pulm Circ 2022; 12:e12044. [PMID: 35506106 PMCID: PMC9052996 DOI: 10.1002/pul2.12044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Revised: 12/22/2021] [Accepted: 01/14/2022] [Indexed: 11/25/2022] Open
Abstract
Periodic repetition of right heart catheterization (RHC) in pulmonary arterial hypertension (PAH) can be challenging. We evaluated the correlation between RHC and cardiopulmonary exercise test (CPET) aiming at CPET use as a potential noninvasive tool for hemodynamic burden evaluation. One hundred and forty‐four retrospective PAH patients who had performed CPET and RHC within 2 months were enrolled. The following analyses were performed: (a) CPET parameters in hemodynamic variables tertiles; (b) position of hemodynamic parameters in the peak end‐tidal carbon dioxide pressure (PETCO2) versus ventilation/carbon dioxide output (VE/VCO2) slope scatterplot, which is a specific hallmark of exercise respiratory abnormalities in PAH; (c) association between CPET and a hemodynamic burden score developed including mean pulmonary arterial pressure (mPAP), pulmonary vascular resistance (PVR), cardiac index, and right atrial pressure. VE/VCO2 slope and peak PETCO2 significantly varied in mPAP and PVR tertiles, while peak oxygen uptake (peak VO2) and O2 pulse varied in the tertiles of all hemodynamic parameters. PETCO2 versus VE/VCO2 slope showed a strong hyperbolic relationship (R2 = 0.7627). Patients with peak PETCO2 > median (26 mmHg) and VE/VCO2 slope < median (44) presented lower mPAP and PVR (p < 0.005) than patients with peak PETCO2 < median and VE/VCO2 slope > median. Multivariate analysis individuated peak VO2 (p = 0.0158) and peak PETCO2 (p = 0.0089) as hemodynamic score independent predictors; the formula 11.584 − 0.0925 × peak VO2 − 0.0811 × peak PETCO2 best predicts the hemodynamic score value from CPET data. A significant correlation was found between estimated and calculated scores (p < 0.0001), with a precise match for patients with mild‐to‐moderate hemodynamic burden (76% of cases). The results of the present study suggest that CPET could allow to estimate the hemodynamic burden in PAH patients.
Collapse
Affiliation(s)
- B Pezzuto
- Centro Cardiologico Monzino IRCCS Milan Italy
| | - R Badagliacca
- Department of Cardiovascular and Respiratory Sciences Sapienza University of Rome Italy
| | - M Muratori
- Centro Cardiologico Monzino IRCCS Milan Italy
| | - S Farina
- Centro Cardiologico Monzino IRCCS Milan Italy
| | - M Bussotti
- Cardiac Rehabilitation Department IRCCS Istituti Clinici Scientifici Maugeri Milan Italy
| | - M Correale
- University Hospital Ospedali Riuniti Foggia Italy
| | - A Bonomi
- Centro Cardiologico Monzino IRCCS Milan Italy
| | - C Vignati
- Centro Cardiologico Monzino IRCCS Milan Italy
| | - S Sciomer
- Department of Cardiovascular and Respiratory Sciences Sapienza University of Rome Italy
| | - S Papa
- Department of Cardiovascular and Respiratory Sciences Sapienza University of Rome Italy
| | - E Palazzo Adriano
- Cardiac Rehabilitation Department IRCCS Istituti Clinici Scientifici Maugeri Milan Italy
| | - P Agostoni
- Centro Cardiologico Monzino IRCCS Milan Italy
- Department of Clinical Sciences and Community Health University of Milan Milan Italy
| |
Collapse
|
10
|
Paolillo S, Salvioni E, Perrone Filardi P, Bonomi A, Sinagra G, Gentile P, Gargiulo P, Scoccia A, Cosentino N, Gugliandolo P, Badagliacca R, Lagioia R, Correale M, Frigerio M, Perna E, Piepoli M, Re F, Raimondo R, Minà C, Clemenza F, Bussotti M, Limongelli G, Gravino R, Passantino A, Magrì D, Parati G, Caravita S, Scardovi AB, Arcari L, Vignati C, Mapelli M, Cattadori G, Cavaliere C, Corrà U, Agostoni P. Corrigendum to "Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction: Insights from the MECKI Score database" [Int J Cardiol. 2020 Oct 15; 317: 103-110. PMID: 32360652]. Int J Cardiol 2021; 333:252. [PMID: 33640418 DOI: 10.1016/j.ijcard.2021.02.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- S Paolillo
- Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy; Mediterranea Cardiocentro, Naples, Italy
| | - E Salvioni
- Centro Cardiologico Monzino, IRCCS, Milano, Italy
| | - P Perrone Filardi
- Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy
| | - A Bonomi
- Centro Cardiologico Monzino, IRCCS, Milano, Italy
| | - G Sinagra
- Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy
| | - P Gentile
- Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy
| | - P Gargiulo
- Department of Advanced Biomedical Sciences, Federico II University of Naples, Italy
| | - A Scoccia
- Centro Cardiologico Monzino, IRCCS, Milano, Italy
| | - N Cosentino
- Centro Cardiologico Monzino, IRCCS, Milano, Italy
| | | | - R Badagliacca
- Dipartimento di Scienze Cardiovascolari, Respiratorie, Nefrologiche, Anestesiologiche e Geriatriche, "Sapienza", Rome University, Rome, Italy
| | - R Lagioia
- Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy
| | - M Correale
- Department of Cardiology, University of Foggia, Foggia, Italy
| | - M Frigerio
- Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda - A.O. Niguarda, Milano, Italy
| | - E Perna
- Dipartimento Cardiologico "A. De Gasperis", Ospedale Cà Granda - A.O. Niguarda, Milano, Italy
| | - M Piepoli
- UOC Cardiologia, G da Saliceto Hospital, Piacenza, Italy
| | - F Re
- Cardiology Division, Cardiac Arrhythmia Center and Cardiomyopathies Unit, San Camillo-Forlanini Hospital, Roma, Italy
| | - R Raimondo
- Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Tradate, Italy
| | - C Minà
- Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy
| | - F Clemenza
- Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation IRCCS - ISMETT, Palermo, Italy
| | - M Bussotti
- Department of Cardiology, Istituti Clinici Scientifici Maugeri IRCCS, Milano, Italy
| | - G Limongelli
- Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy
| | - R Gravino
- Cardiologia SUN, Ospedale Monaldi (Azienda dei Colli), Seconda Università di Napoli, Napoli, Italy
| | - A Passantino
- Division of Cardiology, "S. Maugeri" Foundation, IRCCS, Institute of Cassano Murge, Bari, Italy
| | - D Magrì
- Department of Clinical and Molecular Medicine, Azienda Ospedaliera Sant'Andrea, "Sapienza" Università degli Studi di Roma, Roma, Italy
| | - G Parati
- Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy
| | - S Caravita
- San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy; Department of Management, Information and Production Engineering, University of Bergamo, Dalmine, BG, Italy
| | - A B Scardovi
- Cardiology Division, Santo Spirito Hospital, Roma, Italy
| | - L Arcari
- Cardiology Division, Santo Spirito Hospital, Roma, Italy
| | - C Vignati
- Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy
| | - M Mapelli
- Centro Cardiologico Monzino, IRCCS, Milano, Italy
| | - G Cattadori
- Unità Operativa Cardiologia Riabilitativa, Multimedica IRCCS, Milano, Italy
| | | | - U Corrà
- Fondazione Salvatore Maugeri, IRCCS, Istituto Scientifico di Veruno, Italy
| | - P Agostoni
- Centro Cardiologico Monzino, IRCCS, Milano, Italy; Department of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy.
| | | |
Collapse
|
11
|
Coccè V, Bonomi A, Cavicchini L, Sisto F, Giannì A, Farronato G, Alessandri G, Petrella F, Sordi V, Parati E, Bondiolotti G, Paino F, Pessina A. Paclitaxel Priming of TRAIL Expressing Mesenchymal Stromal Cells (MSCs-TRAIL) Increases Antitumor Efficacy of Their Secretome. Curr Cancer Drug Targets 2020; 21:CCDT-EPUB-111520. [PMID: 33200709 DOI: 10.2174/1568009620666201116112153] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 09/07/2020] [Accepted: 09/16/2020] [Indexed: 12/25/2022]
Abstract
BACKGROUND Adipose tissue derived MSCs engineered with the tumor necrosis factor-related apoptosis-inducing ligand protein (MSCs-TRAIL) have a significant anticancer activity. MSCs, without any genetic modifications, exposed to high doses of chemotherapeutic agents are able to uptake the drug and release it in amount affecting tumor proliferation. The purpose of this study was to verify the ability of MSCs-TRAIL to uptake and release paclitaxel (PTX) by providing an increased antitumor efficacy. METHODS MSCs and MSCs-TRAIL were tested for their sensitivity to Paclitaxel (PTX) by MTT assay and the cells were loaded with PTX according to a standardized procedure. The secretome was analysed by HPLC for the presence of PTX, microarray assay for soluble TRAIL (s-TRAIL) and tested for in vitro anticancer activity. RESULTS MSCs-TRAIL were resistant to PTX and able to incorporate and then release the drug. The secretion of s-TRAIL by PTX loaded MSCs-TRAIL was not inhibited and the PTX delivery together with s-TRAIL secretion resulted into an increased antitumor efficacy of cell secretoma as tested in vitro on human pancreatic carcinoma (CFPAC-1) and glioblastoma (U87-MG). CONCLUSIONS Our result is the first demonstration of the possible merging of two new MSCs therapy approaches based on genetic manipulation and drug delivery. If confirmed in vivo, this could potentiate the efficacy of MSCs-TRAIL and strongly contribute to reduce the toxicity due to the systemic treatment of PTX.
Collapse
Affiliation(s)
- Valentina Coccè
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Arianna Bonomi
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Loredana Cavicchini
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Francesca Sisto
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Aldo Giannì
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Giampietro Farronato
- Department of Biomedical, Surgical and Dental Sciences, Unit of Orthodontics and Paediatric Dentistry, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano. Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan. Italy
| | - Francesco Petrella
- Department of Oncology and Hematology, University of Milan, Milan. Italy
| | - Valeria Sordi
- San Raffaele Diabetes Research Institute; San Raffaele Scientific Institute, Milan. Italy
| | - Eugenio Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan. Italy
| | - Gianpietro Bondiolotti
- Department of Medical Biotechnology and Translational Medicine, University of Milan. Italy
| | - Francesca Paino
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| | - Augusto Pessina
- CRC StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan. Italy
| |
Collapse
|
12
|
Pizzamiglio F, Riva S, Dessanai M, Bonomi A, Fassini G, Casella M, Moltrasio M, Tundo F, Zeppilli P, Tondo C. Atrial fibrillation ablation in athletes: 5-years experience of a single italian third-level center. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.0576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The number of master athletes is increasing and treatment of AF is mandatory for sports continuation. However, few data exist about the effectiveness of catheter ablation (CA) in athletes and the feasibility of resuming vigorous exercise afterwards.
Objectives
Aim of our study was to analyze the efficacy and safety of AF CA in athletes and to evaluate the feasibility of resuming vigorous exercise.
Methods
We report a retrospective registry of athletes referred to our center for AF CA in the last five years. All athletes were previously declared non-eligible to competitive sport because of recurrences of AF or evidence of persistent asymptomatic AF. CA was performed as per practice and recurrences were defined as recrudescence of symptoms and/or any documentation of AF lasting more than 30 sec. At the end of the follow-up all pts were asked about resuming sport.
Results
We ablated 40 athletes (38 males, 95%) with a mean age of 48±13 years. Mean left atrium volume was 36±11 ml/m2 and mean ejection fraction was 61±5%. Distribution between AF characteristics was: 31 (78%) paroxysmal AF, 8 (20%) early-persistent AF, 1 (2%) long-persistent AF.
After a median follow-up of 787 days, 62,5% of athletes were free from recurrences after one CA procedure and mostly without antiarrhythmic drugs (87%). 7 athletes underwent a redo procedure and all of them were then free of recurrences with an overall freedom from recurrences of 84%. No major complication was observed. Athletes practicing endurance sports showed a negative trend in terms of recurrences (p = ns).
Most (72%) of the athletes resumed vigorous exercise after at least 3 months from the CA as per Italian sport protocols.
Conclusions
CA is safe and efficient in treating AF also in athletes. Resuming high intensity sports is often possible after 3 months from CA.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - S.I Riva
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - M.A Dessanai
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - A Bonomi
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - G Fassini
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - M Casella
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - M Moltrasio
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - F Tundo
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| | - P Zeppilli
- Catholic University of the Sacred Heart, Rome, Italy
| | - C Tondo
- Centro Cardiologico Monzino, IRCCS, Milan, Italy
| |
Collapse
|
13
|
Sisto F, Scaltrito MM, Masia C, Bonomi A, Coccè V, Marano G, Haynes RK, Miani A, Farronato G, Taramelli D. Corrigendum to 'In vitro activity of artemisone and artemisinin derivatives against extracellular and intracellular Helicobacter pylori' [International Journal of Antimicrobial Agents 48/1 (2016) 101-105]. Int J Antimicrob Agents 2018; 52:528. [PMID: 30172701 DOI: 10.1016/j.ijantimicag.2018.08.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Francesca Sisto
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy.
| | - Maria Maddalena Scaltrito
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Carla Masia
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Arianna Bonomi
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Valentina Coccè
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Giuseppe Marano
- Unit of Medical Statistics, Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
| | - Richard K Haynes
- Centre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa
| | - Alessandro Miani
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Giampietro Farronato
- Dipartimento di Scienze Biomediche, Chirurgiche ed Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milan, Italy
| | - Donatella Taramelli
- Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
14
|
Cosentino N, Campodonico J, Faggiano P, Milazzo V, Rubino M, De Metrio M, Bonomi A, Barbieri S, Marenzi G. P3678Elaboration and validation of a new score based on the PEGASUS-TIMI 54 criteria for 1-year risk stratification of patients with acute myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- N Cosentino
- Cardiology Center Monzino IRCCS, Milan, Italy
| | | | - P Faggiano
- Civil Hospital of Brescia, Brescia, Italy
| | - V Milazzo
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M Rubino
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - M De Metrio
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - A Bonomi
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - S Barbieri
- Cardiology Center Monzino IRCCS, Milan, Italy
| | - G Marenzi
- Cardiology Center Monzino IRCCS, Milan, Italy
| |
Collapse
|
15
|
Mendes F, Dias M, Ferraz A, Milagres A, Santos J, Bonomi A. Techno-economic impacts of varied compositional profiles of sugarcane experimental hybrids on a biorefinery producing sugar, ethanol and electricity. Chem Eng Res Des 2017. [DOI: 10.1016/j.cherd.2017.06.023] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
16
|
Cosentino N, Campodonico J, Milazzo V, De Metrio M, Rubino M, Marana I, Moltrasio M, Bonomi A, Faggiano P, Marenzi G. P36391-year risk stratification of patients with acute myocardial infarction according to the pegasus-timi 54 criteria. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3639] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Cavalca V, Rocca B, Veglia F, Petrucci G, Porro B, Myasoedova V, De Cristofaro R, Turnu L, Bonomi A, Songia P, Cavallotti L, Zanobini M, Camera M, Alamanni F, Parolari A, Patrono C, Tremoli E. On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. Clin Pharmacol Ther 2017; 102:849-858. [DOI: 10.1002/cpt.702] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 03/27/2017] [Accepted: 03/29/2017] [Indexed: 12/11/2022]
Affiliation(s)
- V Cavalca
- Monzino Cardiology Center, IRCCS; Milan Italy
- University of Milan; Milan Italy
| | - B Rocca
- Department of Pharmacology; Catholic University; Rome Italy
| | - F Veglia
- Monzino Cardiology Center, IRCCS; Milan Italy
| | - G Petrucci
- Department of Pharmacology; Catholic University; Rome Italy
| | - B Porro
- Monzino Cardiology Center, IRCCS; Milan Italy
| | | | | | - L Turnu
- Monzino Cardiology Center, IRCCS; Milan Italy
- University of Milan; Milan Italy
| | - A Bonomi
- Monzino Cardiology Center, IRCCS; Milan Italy
| | - P Songia
- Monzino Cardiology Center, IRCCS; Milan Italy
- University of Milan; Milan Italy
| | | | - M Zanobini
- Monzino Cardiology Center, IRCCS; Milan Italy
| | - M Camera
- Monzino Cardiology Center, IRCCS; Milan Italy
- University of Milan; Milan Italy
| | - F Alamanni
- Monzino Cardiology Center, IRCCS; Milan Italy
- University of Milan; Milan Italy
| | - A Parolari
- Policlinico San Donato Hospital, IRCCS; San Donato Milanese Italy
| | - C Patrono
- Department of Pharmacology; Catholic University; Rome Italy
| | - E Tremoli
- Monzino Cardiology Center, IRCCS; Milan Italy
| |
Collapse
|
18
|
Silva JFL, Selicani MA, Junqueira TL, Klein BC, Vaz Júnior S, Bonomi A. Integrated furfural and first generation bioethanol production: process simulation and techno-economic analysis. Braz J Chem Eng 2017. [DOI: 10.1590/0104-6632.20170343s20150643] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- J. F. L. Silva
- Centro Nacional de Pesquisa em Energia e Materiais, Brazil; UNICAMP, Brazil; Embrapa Agroenergia, Brazil
| | - M. A. Selicani
- Centro Nacional de Pesquisa em Energia e Materiais, Brazil
| | | | - B. C. Klein
- Centro Nacional de Pesquisa em Energia e Materiais, Brazil; UNICAMP, Brazil
| | | | - A. Bonomi
- Centro Nacional de Pesquisa em Energia e Materiais, Brazil; UNICAMP, Brazil
| |
Collapse
|
19
|
Bonomi A, Ghezzi E, Pascucci L, Aralla M, Ceserani V, Pettinari L, Coccè V, Guercio A, Alessandri G, Parati E, Brini AT, Zeira O, Pessina A. Effect of canine mesenchymal stromal cells loaded with paclitaxel on growth of canine glioma and human glioblastoma cell lines. Vet J 2017; 223:41-47. [PMID: 28671070 DOI: 10.1016/j.tvjl.2017.05.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 05/03/2017] [Accepted: 05/14/2017] [Indexed: 01/03/2023]
Abstract
This study investigated whether canine mesenchymal stromal cells (cMSCs) are able to take up and release paclitaxel (PTX) in active form, and therefore whether they have potential as a tool for therapeutic delivery of this drug. cMSCs from bone marrow and adipose tissue were isolated, expanded and characterised phenotypically. cMSCs were loaded with PTX (cMSCs-PTX) and their capacity for release of PTX was determined by their effect on proliferation of cancer cells. cMSCs-PTX derived from bone marrow and adipose tissue were able to take up and then release active PTX. cMSCs-PTC inhibited proliferation of the canine glioma cell line J3T, and the human glioblastoma cell lines T98G and U87MG. The potential of canine cMSCs-PTX for treatment of canine gliomas should be investigated further.
Collapse
Affiliation(s)
- A Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133 Milan, Italy
| | - E Ghezzi
- Veterinary Hospital San Michele, via I Maggio 37, 26838 Tavazzano con Villavesco, Lodi, Italy
| | - L Pascucci
- Department of Veterinary Medicine, University of Perugia, via San Costanzo 4, 06126 Perugia, Italy
| | - M Aralla
- Veterinary Hospital San Michele, via I Maggio 37, 26838 Tavazzano con Villavesco, Lodi, Italy
| | - V Ceserani
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, via Celoria 11, 20133 Milan, Italy
| | - L Pettinari
- Veterinary Hospital San Michele, via I Maggio 37, 26838 Tavazzano con Villavesco, Lodi, Italy
| | - V Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133 Milan, Italy
| | - A Guercio
- Area Diagnostica Virologica dell'Istituto Zooprofilattico Sperimentale della Sicilia 'A Mirri', Palermo, Italy
| | - G Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, via Celoria 11, 20133 Milan, Italy
| | - E Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, via Celoria 11, 20133 Milan, Italy
| | - A T Brini
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133 Milan, Italy; IRCCS Galeazzi Orthopaedic Institute, Milan, Italy
| | - O Zeira
- Veterinary Hospital San Michele, via I Maggio 37, 26838 Tavazzano con Villavesco, Lodi, Italy
| | - A Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133 Milan, Italy.
| |
Collapse
|
20
|
Pacioni S, D'Alessandris QG, Giannetti S, Morgante L, Coccè V, Bonomi A, Buccarelli M, Pascucci L, Alessandri G, Pessina A, Ricci-Vitiani L, Falchetti ML, Pallini R. Human mesenchymal stromal cells inhibit tumor growth in orthotopic glioblastoma xenografts. Stem Cell Res Ther 2017; 8:53. [PMID: 28279193 PMCID: PMC5345323 DOI: 10.1186/s13287-017-0516-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2016] [Revised: 01/27/2017] [Accepted: 02/21/2017] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Mesenchymal stem/stromal cells (MSCs) represent an attractive tool for cell-based cancer therapy mainly because of their ability to migrate to tumors and to release bioactive molecules. However, the impact of MSCs on tumor growth has not been fully established. We previously demonstrated that murine MSCs show a strong tropism towards glioblastoma (GBM) brain xenografts and that these cells are able to uptake and release the chemotherapeutic drug paclitaxel (PTX), maintaining their tropism towards the tumor. Here, we address the therapy-relevant issue of using MSCs from human donors (hMSCs) for local or systemic administration in orthotopic GBM models, including xenografts of patient-derived glioma stem cells (GSCs). METHODS U87MG or GSC1 cells expressing the green fluorescent protein (GFP) were grafted onto the striatum of immunosuppressed rats. Adipose hMSCs (Ad-hMSCs), fluorescently labeled with the mCherry protein, were inoculated adjacent to or into the tumor. In rats bearing U87MG xenografts, systemic injections of Ad-hMSCs or bone marrow (BM)-hMSCs were done via the femoral vein or carotid artery. In each experiment, either PTX-loaded or unloaded hMSCs were used. To characterize the effects of hMSCs on tumor growth, we analyzed survival, tumor volume, tumor cell proliferation, and microvascular density. RESULTS Overall, the AD-hMSCs showed remarkable tropism towards the tumor. Intracerebral injection of Ad-hMSCs significantly improved the survival of rats with U87MG xenografts. This effect was associated with a reduction in tumor growth, tumor cell proliferation, and microvascular density. In GSC1 xenografts, intratumoral injection of Ad-hMSCs depleted the tumor cell population and induced migration of resident microglial cells. Overall, PTX loading did not significantly enhance the antitumor potential of hMSCs. Systemically injected Ad- and BM-hMSCs homed to tumor xenografts. The efficiency of hMSC homing ranged between 0.02 and 0.5% of the injected cells, depending both on the route of cell injection and on the source from which the hMSCs were derived. Importantly, systemically injected PTX-loaded hMSCs that homed to the xenograft induced cytotoxic damage to the surrounding tumor cells. CONCLUSIONS hMSCs have a therapeutic potential in GBM brain xenografts which is also expressed against the GSC population. In this context, PTX loading of hMSCs seems to play a minor role.
Collapse
Affiliation(s)
- Simone Pacioni
- Institute of Neurosurgery, Università Cattolica del Sacro Cuore, Rome, Italy.,CNR-Institute of Cell Biology and Neurobiology (IBCN), Rome, Italy
| | | | - Stefano Giannetti
- Institute of Anatomy, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Liliana Morgante
- Institute of Anatomy, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Arianna Bonomi
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Mariachiara Buccarelli
- Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Giulio Alessandri
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Lucia Ricci-Vitiani
- Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
| | | | - Roberto Pallini
- Institute of Neurosurgery, Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
21
|
Crimes J, Isafiade A, Fraser D, Short M, Bonomi A. Assessment of pre-treatment technologies for bioethanol production from sugarcane bagasse considering economics and environmental impact. ASIA-PAC J CHEM ENG 2016. [DOI: 10.1002/apj.2066] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J. Crimes
- University of Cape Town; Private Bag X3, Upper Campus Rondebosch 7701 South Africa
| | - A.J. Isafiade
- University of Cape Town; Private Bag X3, Upper Campus Rondebosch 7701 South Africa
| | - D.M. Fraser
- University of Cape Town; Private Bag X3, Upper Campus Rondebosch 7701 South Africa
| | - M. Short
- University of Cape Town; Private Bag X3, Upper Campus Rondebosch 7701 South Africa
| | - A. Bonomi
- Laboratório Nacional de Ciência e Tecnologia do Bioetanol (CTBE); Caixa Postal 6170 CEP 13083-970 Campinas-SP Brazil
| |
Collapse
|
22
|
Ceserani V, Ferri A, Berenzi A, Benetti A, Ciusani E, Pascucci L, Bazzucchi C, Coccè V, Bonomi A, Pessina A, Ghezzi E, Zeira O, Ceccarelli P, Versari S, Tremolada C, Alessandri G. Angiogenic and anti-inflammatory properties of micro-fragmented fat tissue and its derived mesenchymal stromal cells. Vasc Cell 2016; 8:3. [PMID: 27547374 PMCID: PMC4991117 DOI: 10.1186/s13221-016-0037-3] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2016] [Accepted: 07/27/2016] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Adipose-derived mesenchymal stromal cells (Ad-MSCs) are a promising tool for advanced cell-based therapies. They are routinely obtained enzymatically from fat lipoaspirate (LP) as SVF, and may undergo prolonged ex vivo expansion, with significant senescence and decline in multipotency. Besides, these techniques have complex regulatory issues, thus incurring in the compelling requirements of GMP guidelines. Hence, availability of a minimally manipulated, autologous adipose tissue would have remarkable biomedical and clinical relevance. For this reason, a new device, named Lipogems® (LG), has been developed. This ready-to-use adipose tissue cell derivate has been shown to have in vivo efficacy upon transplantation for ischemic and inflammatory diseases. To broaden our knowledge, we here investigated the angiogenic and anti-inflammatory properties of LG and its derived MSC (LG-MSCs) population. METHODS Human LG samples and their LG-MSCs were analyzed by immunohistochemistry for pericyte, endothelial and mesenchymal stromal cell marker expression. Angiogenesis was investigated testing the conditioned media (CM) of LG (LG-CM) and LG-MSCs (LG-MSCs-CM) on cultured endothelial cells (HUVECs), evaluating proliferation, cord formation, and the expression of the adhesion molecules (AM) VCAM-1 and ICAM-1. The macrophage cell line U937 was used to evaluate the anti-inflammatory properties, such as migration, adhesion on HUVECs, and release of RANTES and MCP-1. RESULTS Our results indicate that LG contained a very high number of mesenchymal cells expressing NG2 and CD146 (both pericyte markers) together with an abundant microvascular endothelial cell (mEC) population. Substantially, both LG-CM and LG-MSC-CM increased cord formation, inhibited endothelial ICAM-1 and VCAM-1 expression following TNFα stimulation, and slightly improved HUVEC proliferation. The addition of LG-CM and LG-MSC-CM strongly inhibited U937 migration upon stimulation with the chemokine MCP-1, reduced their adhesion on HUVECs and significantly suppressed the release of RANTES and MCP-1. CONCLUSIONS Our data indicate that LG micro-fragmented adipose tissue retains either per se, or in its embedded MSCs content, the capacity to induce vascular stabilization and to inhibit several macrophage functions involved in inflammation.
Collapse
Affiliation(s)
- Valentina Ceserani
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Via Celoria 11, 20131 Milan, Italy
| | - Anna Ferri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Via Celoria 11, 20131 Milan, Italy
| | - Angiola Berenzi
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, University of Brescia, Brescia, Italy
| | - Anna Benetti
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, University of Brescia, Brescia, Italy
| | - Emilio Ciusani
- Laboratory of Clinical Pathology and Neurogenetic Medicine, Fondazione IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Cinzia Bazzucchi
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Erica Ghezzi
- San Michele Veterinary Hospital, Tavezzano con Villavesco, Lodi, Italy
| | - Offer Zeira
- San Michele Veterinary Hospital, Tavezzano con Villavesco, Lodi, Italy
| | - Piero Ceccarelli
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | | | | | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Via Celoria 11, 20131 Milan, Italy
| |
Collapse
|
23
|
Sisto F, Scaltrito MM, Masia C, Bonomi A, Coccè V, Marano G, Haynes RK, Miani A, Farronato G, Taramelli D. In vitro activity of artemisone and artemisinin derivatives against extracellular and intracellular Helicobacter pylori. Int J Antimicrob Agents 2016; 48:101-105. [DOI: 10.1016/j.ijantimicag.2016.03.018] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 03/23/2016] [Accepted: 03/28/2016] [Indexed: 12/21/2022]
|
24
|
Bonomi A, Steimberg N, Benetti A, Berenzi A, Alessandri G, Pascucci L, Boniotti J, Coccè V, Sordi V, Pessina A, Mazzoleni G. Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. Hematol Oncol 2016; 35:693-702. [PMID: 27283119 DOI: 10.1002/hon.2306] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 03/31/2016] [Accepted: 04/21/2016] [Indexed: 02/03/2023]
Abstract
Multiple myeloma is an aggressive tumour able to suppress osteoblastogenesis probably mediated by bone marrow mesenchymal stromal cells (BM-MSCs) that can also support plasma cell growth/survival. The use of MSCs for multiple myeloma therapy is a controversial topic because of the contradictory results on the capacity of MSCs to inhibit or to promote cancer growth. Our previous studies demonstrated that MSCs could be loaded with Paclitaxel (PTX) and used to deliver the drug in situ in amount affecting tumour growth (in vitro and in vivo). Therefore, independently on the discussed action of MSCs in myeloma, MSCs could represent a 'trojan horse' to vehicle and deliver anti-tumour agents into bone marrow. This study confirms, by an in vitro 3D dynamic culture system, that PTX loaded BM-MSCs (PTXr-MSCs) are active on the proliferation of RPMI 8226, a human myeloma cell line. Our results demonstrated a dramatic suppression of myeloma cell growth by PTXr-MSCs, suggesting that drug loaded MSCs could be a tool to deliver drug into the bone marrow. Drug releasing MSCs provide a therapeutic approach to potentiate the existing treatments against a very aggressive malignancy as multiple myeloma. Copyright © 2016 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Nathalie Steimberg
- Laboratory of Tissue Engineering, Anatomy and Physiopathology Unit, Department of Clinical and Experimental Sciences, School of Medicine, University of Brescia, Brescia, Italy
| | - Anna Benetti
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, School of Medicine, University of Brescia, Brescia, Italy
| | - Angiola Berenzi
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, School of Medicine, University of Brescia, Brescia, Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Jennifer Boniotti
- Laboratory of Tissue Engineering, Anatomy and Physiopathology Unit, Department of Clinical and Experimental Sciences, School of Medicine, University of Brescia, Brescia, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Valeria Sordi
- Diabetes Research Institute, IRCCS S. Raffaele Scientific Institute, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Giovanna Mazzoleni
- Laboratory of Tissue Engineering, Anatomy and Physiopathology Unit, Department of Clinical and Experimental Sciences, School of Medicine, University of Brescia, Brescia, Italy
| |
Collapse
|
25
|
Werba J, Giroli M, Simonelli N, Vigo L, Amato M, Gorini A, Bonomi A, Veglia F, Tremoli E. OC06_02 Risk Awareness in a New Community Program for Cardiovascular Health in Milan, Italy. Glob Heart 2016. [DOI: 10.1016/j.gheart.2016.03.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
26
|
Brini AT, Coccè V, Ferreira LMJ, Giannasi C, Cossellu G, Giannì AB, Angiero F, Bonomi A, Pascucci L, Falchetti ML, Ciusani E, Bondiolotti G, Sisto F, Alessandri G, Pessina A, Farronato G. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel. Expert Opin Drug Deliv 2016; 13:789-98. [PMID: 26986001 DOI: 10.1517/17425247.2016.1167037] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE Gingival tissue is composed of cell types that contribute to the body's defense against many agents in oral environment, wound healing and tissue regeneration. Thanks to their easy and scarcely invasive withdrawal procedure, interdental papilla provide a good source of mesenchymal stromal cells (GinPa-MSCs). We isolated GinPa-MSCs and verified their ability to uptake/release the anticancer agent Paclitaxel (PTX). METHODS In vitro expanded GinPa-MSCs were characterized for CD markers by FACS, tested for differentiation ability and analyzed by TEM. Their ability to uptake/release PTX was assessed according to a standardized procedure. RESULTS The CD expression and chondro-adipo-osteo differentiation ability confirmed the mesenchymal feature of GinPa-MSCs. Surprisingly, 28% of GinPa-MSCs expressed CD14 marker and had an impressive pinocytotic activity. GinPa-MSCs were able to take up and release a sufficient amount of PTX to demonstrate effective in vitro activity against pancreatic carcinoma cells, suggesting that the drug was not inactivated. CONCLUSIONS The procedure to obtain MSCs from interdental papilla is less invasive than that used for both bone marrow and adipose tissue, GinPa-MSCs are easy to expand and can be efficiently loaded with PTX. Taken together these qualities suggest that GinPa-MSCs may prove to be a good tool for cell-mediated drug delivery in cancer, particularly if related to stomatognathic system.
Collapse
Affiliation(s)
- Anna Teresa Brini
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy.,b I.R.C.C.S. Istituto Ortopedico Galeazzi , Milan , Italy
| | - Valentina Coccè
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy.,d Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Maxillofacial and Dental Unit, Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Lorena M Josè Ferreira
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Chiara Giannasi
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Gianguido Cossellu
- c Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Unit of Orthodontics and Paediatric Dentistry, School of Dentistry, Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Aldo Bruno Giannì
- d Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Maxillofacial and Dental Unit, Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Francesca Angiero
- e Department of Medical Sciences and Diagnostic Integrated , S. Martino Hospital, University of Genoa , Genoa Italy
| | - Arianna Bonomi
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Luisa Pascucci
- f Department of Veterinary Medicine , University of Perugia , Perugia , Italy
| | | | - Emilio Ciusani
- h Laboratory of Clinical Pathology and Neurogenetic Medicine , Fondazione IRCCS Neurological Institute Carlo Besta , Milan , Italy
| | - Gianpietro Bondiolotti
- i Department of Medical Biotechnology and Translational Medicine , University of Milan , Milan , Italy
| | - Francesca Sisto
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Giulio Alessandri
- j Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases , IRCCS Neurological Institute C. Besta , Milan , Italy
| | - Augusto Pessina
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| | - Giampietro Farronato
- a Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy.,c Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Unit of Orthodontics and Paediatric Dentistry, School of Dentistry, Department of Biomedical, Surgical and Dental Sciences , University of Milan , Milan , Italy
| |
Collapse
|
27
|
Superchi P, Talarico L, Beretti V, Bonomi A. Effect of dietary administration of oil extract from rosemary on reproductive efficiency in boars. Italian Journal of Animal Science 2016. [DOI: 10.4081/ijas.2005.2s.479] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
28
|
Coccè V, Vitale A, Colombo S, Bonomi A, Sisto F, Ciusani E, Alessandri G, Parati E, Brambilla P, Brambilla M, La Porta CA, Pessina A. Human skin-derived fibroblasts used as a 'Trojan horse' for drug delivery. Clin Exp Dermatol 2016; 41:417-24. [PMID: 26899383 DOI: 10.1111/ced.12811] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/29/2015] [Indexed: 12/24/2022]
Abstract
BACKGROUND Drug toxicity currently represents the main challenge of tumour chemotherapy. Our group recently developed a new method for drug delivery inspired by the 'Trojan Horse' concept. Human mesenchymal stem cells (hMSCs) have been shown to play the role of new 'horses' in delivering anti-tumour agents, without involving any genetic manipulation. As human stromal dermal fibroblasts (hSDFs) represent an interesting alternative to hMSCs, being easy to isolate, they could be an ideal candidate for this kind of procedure. AIM To investigate whether hSDFs can take up and deliver paclitaxel (PTX) in sufficient concentrations to inhibit a very aggressive melanoma tumour (IgR39) in vitro. METHODS hSDFs were primed with high doses of PTX, and then the effect of drug delivery on IgR39 melanoma proliferation in vitro was evaluated using several assays (antiproliferation, transwell cocultures, rosette assays and colony growth assays). Furthermore, the cell cycle and PTX uptake/release mechanism of hSDFs were studied both under both normal and hypoxic conditions. RESULTS hSDFs incorporated PTX and then released it with unaffected pharmacological activity, inhibiting human IgR39 melanoma growth in vitro. The hypoxic conditions did not induce changes in cell cycle pattern and the uptake-release mechanism with PTX was not affected. CONCLUSIONS hSDFs can be used as a Trojan horse, as the released drug was functionally active. These results indicated that these cells could be used for clinical treatment as the drug was released into the cellular environment and the primed cells underwent apoptosis.
Collapse
Affiliation(s)
- V Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - A Vitale
- Department of Biosciences, Molecular Oncology Laboratory, University of Milan, Milan, Italy
| | - S Colombo
- Department of Biosciences, Molecular Oncology Laboratory, University of Milan, Milan, Italy
| | - A Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - F Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - E Ciusani
- Department of Diagnostics and Applied Technology, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - G Alessandri
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - E Parati
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - P Brambilla
- Department of Diagnostic Services, Desio and Vimercate's Hospital, Milan, Italy
| | - M Brambilla
- Department of Diagnostic Services, Desio and Vimercate's Hospital, Milan, Italy
| | - C A La Porta
- Department of Biosciences, Molecular Oncology Laboratory, University of Milan, Milan, Italy
| | - A Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| |
Collapse
|
29
|
Mariotti M, Colognato R, Rimoldi M, Rizzetto M, Sisto F, Cocce V, Bonomi A, Parati E, Alessandri G, Bagnati R, Pessina A. Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity. Anticancer Agents Med Chem 2015; 15:400-5. [PMID: 24942547 DOI: 10.2174/1871520614666140618113441] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 06/06/2014] [Accepted: 06/16/2014] [Indexed: 11/22/2022]
Abstract
To improve the drug delivery efficiency on target cells, many strategies have been developed including Mesenchymal Stromal Cells (MSCs) approaches. In a previous study, we found that bone-marrow-derived MSCs (BM-MSCs) were able to incorporate and release the anti-tumor and anti-angiogenic drug, Paclitaxel (PTX). In this study, we evaluated the stability of PTX in standard cell culture conditions by analyzing the metabolites produced by MSCs after their incorporation of the drug. We are able to show that MSCs do not release either 3-OH-PTX or 6-OH-PTX metabolites (having a lower anticancer activity) but release an active PTX molecule together with the isomer 7-Epitaxol, is known to maintain the whole biological activity. This confirms that the simple procedure of MSCs priming with a drug (without any genetic cell manipulation), in our case PTX, does not modify the activity of the molecule and provides a new biological-device to carry and deliver PTX in tumor sites, by contributing to improve drug efficacy and target selectivity in cancer therapy.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133 Milan, Italy.
| |
Collapse
|
30
|
Bonomi A, Sordi V, Dugnani E, Ceserani V, Dossena M, Coccè V, Cavicchini L, Ciusani E, Bondiolotti G, Piovani G, Pascucci L, Sisto F, Alessandri G, Piemonti L, Parati E, Pessina A. Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells. Cytotherapy 2015; 17:1687-95. [PMID: 26481416 DOI: 10.1016/j.jcyt.2015.09.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 09/10/2015] [Accepted: 09/15/2015] [Indexed: 12/12/2022]
Abstract
BACKGROUND AIMS Pancreatic cancer (pCa) is a tumor characterized by a fibrotic state and associated with a poor prognosis. The observation that mesenchymal stromal cells (MSCs) migrate toward inflammatory micro-environments and engraft into tumor stroma after systemic administration suggested new therapeutic approaches with the use of engineered MSCs to deliver and produce anti-cancer molecules directly within the tumor. Previously, we demonstrated that without any genetic modifications, MSCs are able to deliver anti-cancer drugs. MSCs loaded with paclitaxel by exposure to high concentrations release the drug both in vitro and in vivo, inhibiting tumor proliferation. On the basis of these observations, we evaluated the ability of MSCs (from bone marrow and pancreas) to uptake and release gemcitabine (GCB), a drug widely used in pCa treatment. METHODS MSCs were primed by 24-h exposure to 2000 ng/mL of GCB. The anti-tumor potential of primed MSCs was then investigated by in vitro anti-proliferation assays with the use of CFPAC-1, a pancreatic tumor cell line sensitive to GCB. The uptake/release ability was confirmed by means of high-performance liquid chromatography analysis. A cell-cycle study and secretome evaluation were also conducted to better understand the characteristics of primed MSCs. RESULTS GCB-releasing MSCs inhibit the growth of a human pCa cell line in vitro. CONCLUSIONS The use of MSCs as a "trojan horse" can open the way to a new pCa therapeutic approach; GCB-loaded MSCs that integrate into the tumor mass could deliver much higher concentrations of the drug in situ than can be achieved by intravenous injection.
Collapse
Affiliation(s)
- Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Valeria Sordi
- Diabetes Research Institute, IRCCS S. Raffaele Scientific Institute, Milan, Italy
| | - Erica Dugnani
- Diabetes Research Institute, IRCCS S. Raffaele Scientific Institute, Milan, Italy
| | - Valentina Ceserani
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Marta Dossena
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Loredana Cavicchini
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Emilio Ciusani
- Laboratory of Clinical Pathology and Neurogenetic Medicine, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Gianpietro Bondiolotti
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - Giovanna Piovani
- Biology and Genetics Division, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Lorenzo Piemonti
- Diabetes Research Institute, IRCCS S. Raffaele Scientific Institute, Milan, Italy
| | - Eugenio Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| |
Collapse
|
31
|
Pacioni S, D'Alessandris QG, Giannetti S, Morgante L, De Pascalis I, Coccè V, Bonomi A, Pascucci L, Alessandri G, Pessina A, Falchetti ML, Pallini R. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts. Stem Cell Res Ther 2015; 6:194. [PMID: 26445228 PMCID: PMC4594910 DOI: 10.1186/s13287-015-0185-z] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 09/09/2015] [Accepted: 09/16/2015] [Indexed: 01/14/2023] Open
Abstract
INTRODUCTION The goal of cancer chemotherapy is targeting tumor cells and/or tumor-associated microvessels with the lowest systemic toxicity. Mesenchymal stromal cells (MSCs) are promising vehicles for selective drug delivery due to their peculiar ability to home to pathological tissues. We previously showed that MSCs are able to uptake and subsequently to release the chemotherapeutic compound Paclitaxel (PTX) and to impair the growth of subcutaneous glioblastoma multiforme (GBM) xenografts. Here we used an orthotopic GBM model 1) to assess whether PTX-loaded MSCs (PTX-MSCs) retain a tropism towards the tumor cells in the brain context, and 2) to characterize the cytotoxic damage induced by MSCs-driven PTX release in the tumor microenvironment. METHODS U87MG GBM cells were fluorescently labeled with the mCherry protein and grafted onto the brain of immunosuppressed rats. In adjacent brain regions, we injected green fluorescent protein-expressing murine MSCs, either loaded with PTX or unloaded. After 1 week survival, the xenografted brain was assessed by confocal microscopy for PTX-induced cell damage. RESULTS Overall, MSCs showed remarkable tropism towards the tumor. In rats grafted with PTX-MSCs, the nuclei of U87MG cells showed changes that are typically induced by PTX, including multi-spindle mitoses, centrosome number alterations, and nuclear fragmentation. Multi-spindle mitoses resulted in multinucleated cells that were significantly higher in tumors co-grafted with PTX-MSCs than in controls. Nuclear changes did not occur in astrocytes and neurons surrounding the tumor. CONCLUSIONS MSCs appear particularly suited for anti-neoplastic drug delivery in the brain since PTX-specific damage of GBM cells can be achieved avoiding side effects to the normal tissue.
Collapse
Affiliation(s)
- Simone Pacioni
- Institute of Neurosurgery, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy. .,CNR-Institute of Cell Biology and Neurobiology (IBCN), via del Fosso di Fiorano 64, 00143, Rome, Italy.
| | | | - Stefano Giannetti
- Institute of Anatomy, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
| | - Liliana Morgante
- Institute of Anatomy, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
| | - Ivana De Pascalis
- Institute of Pathology, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133, Milan, Italy.
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133, Milan, Italy.
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, via San Costanzo 4, 06126, Perugia, Italy.
| | - Giulio Alessandri
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, via Giovanni Celoria 11, 20133, Milan, Italy.
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, via Pascal 36, 20133, Milan, Italy.
| | - Maria Laura Falchetti
- CNR-Institute of Cell Biology and Neurobiology (IBCN), via del Fosso di Fiorano 64, 00143, Rome, Italy.
| | - Roberto Pallini
- Institute of Neurosurgery, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Rome, Italy.
| |
Collapse
|
32
|
Bonomi A, Silini A, Vertua E, Signoroni PB, Coccè V, Cavicchini L, Sisto F, Alessandri G, Pessina A, Parolini O. Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study. Stem Cell Res Ther 2015; 6:155. [PMID: 26315881 PMCID: PMC4552458 DOI: 10.1186/s13287-015-0140-z] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Revised: 07/29/2015] [Accepted: 07/29/2015] [Indexed: 12/31/2022] Open
Abstract
INTRODUCTION In the context of drug delivery, mesenchymal stromal cells (MSCs) from bone marrow and adipose tissue have emerged as interesting candidates due to their homing abilities and capacity to carry toxic loads, while at the same time being highly resistant to the toxic effects. Amongst the many sources of MSCs which have been identified, the human term placenta has attracted particular interest due to its unique, tissue-related characteristics, including its high cell yield and virtually absent expression of human leukocyte antigens and co-stimulatory molecules. Under basal, non-stimulatory conditions, placental MSCs also possess basic characteristics common to MSCs from other sources. These include the ability to secrete factors which promote cell growth and tissue repair, as well as immunomodulatory properties. The aim of this study was to investigate MSCs isolated from the amniotic membrane of human term placenta (hAMSCs) as candidates for drug delivery in vitro. METHODS We primed hAMSCs from seven different donors with paclitaxel (PTX) and investigated their ability to resist the cytotoxic effects of PTX, to upload the drug, and to release it over time. We then analyzed whether the uptake and release of PTX was sufficient to inhibit proliferation of CFPAC-1, a pancreatic tumor cell line sensitive to PTX. RESULTS For the first time, our study shows that hAMSCs are highly resistant to PTX and are not only able to uptake the drug, but also release it over time. Moreover, we show that PTX is released from hAMSCs in a sufficient amount to inhibit tumor cell proliferation, whilst some of the PTX is also retained within the cells. CONCLUSION Taken together, for the first time our results show that placental stem cells can be used as vehicles for the delivery of cytotoxic agents.
Collapse
Affiliation(s)
- Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| | - Antonietta Silini
- Centro di Ricerca E. Menni, Fondazione Poliambulanza-Istituto Ospedaliero, Via Bissolati, 57 I-25124, Brescia, Italy.
| | - Elsa Vertua
- Centro di Ricerca E. Menni, Fondazione Poliambulanza-Istituto Ospedaliero, Via Bissolati, 57 I-25124, Brescia, Italy.
| | - Patrizia Bonassi Signoroni
- Centro di Ricerca E. Menni, Fondazione Poliambulanza-Istituto Ospedaliero, Via Bissolati, 57 I-25124, Brescia, Italy.
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| | - Loredana Cavicchini
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| | - Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute C. Besta, Milan, Italy.
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| | - Ornella Parolini
- Centro di Ricerca E. Menni, Fondazione Poliambulanza-Istituto Ospedaliero, Via Bissolati, 57 I-25124, Brescia, Italy.
| |
Collapse
|
33
|
Pessina A, Leonetti C, Artuso S, Benetti A, Dessy E, Pascucci L, Passeri D, Orlandi A, Berenzi A, Bonomi A, Coccè V, Ceserani V, Ferri A, Dossena M, Mazzuca P, Ciusani E, Ceccarelli P, Caruso A, Portolani N, Sisto F, Parati E, Alessandri G. Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. J Exp Clin Cancer Res 2015; 34:82. [PMID: 26264809 PMCID: PMC4534150 DOI: 10.1186/s13046-015-0200-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/22/2015] [Accepted: 08/04/2015] [Indexed: 12/21/2022]
Abstract
BACKGROUND Mesenchymal stromal cells (MSCs) are considered an important therapeutic tool in cancer therapy. They possess intrinsic therapeutic potential and can also be in vitro manipulated and engineered to produce therapeutic molecules that can be delivered to the site of diseases, through their capacity to home pathological tissues. We have recently demonstrated that MSCs, upon in vitro priming with anti-cancer drug, become drug-releasing mesenchymal cells (Dr-MCs) able to strongly inhibit cancer cells growth. METHODS Murine mesenchymal stromal cells were loaded with Paclitaxel (Dr-MCsPTX) according to a standardized procedure and their ability to inhibit the growth of a murine B16 melanoma was verified by in vitro assays. The anti-metastatic activity of Dr-MCsPTX was then studied in mice injected i.v. with B16 melanoma cells that produced lung metastatic nodules. Lung nodules were counted under a dissecting stereomicroscope and metastasis investigated by histological analysis. RESULTS We found that three i.v. injections of Dr-MCsPTX on day 5, 10 and 15 after tumor injection almost completely abolished B16 lung metastasis. Dr-MCsPTX arrested into lung by interacting with endothelium and migrate toward cancer nodule through a complex mechanism involving primarily mouse lung stromal cells (mL-StCs) and SDF-1/CXCR4/CXCR7 axis. CONCLUSIONS Our results show for the first time that Dr-MCsPTX are very effective to inhibit lung metastasis formation. Actually, a cure for lung metastasis in humans is mostly unlikely and we do not know whether a therapy combining engineered MSCs and Dr-MCs may work synergistically. However, we think that our approach using Dr-MCs loaded with PTX may represent a new valid and additive therapeutic tool to fight lung metastases and, perhaps, primary lung cancers in human.
Collapse
Affiliation(s)
- Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, Milan, 20133, Italy.
| | - Carlo Leonetti
- Experimental Chemotherapy Laboratory, Regina Elena National Cancer Institute, Rome, Italy
| | - Simona Artuso
- Experimental Chemotherapy Laboratory, Regina Elena National Cancer Institute, Rome, Italy
| | - Anna Benetti
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, University of Brescia, Brescia, Italy
| | - Enrico Dessy
- Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Daniela Passeri
- Department of Biopathology and Image Diagnostics, Anatomic Pathology Institute, University of Rome 'Tor Vergata', Rome, Italy
| | - Augusto Orlandi
- Department of Biopathology and Image Diagnostics, Anatomic Pathology Institute, University of Rome 'Tor Vergata', Rome, Italy
| | - Angiola Berenzi
- Department of Clinical and Experimental Sciences, Institute of Pathological Anatomy, University of Brescia, Brescia, Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, Milan, 20133, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, Milan, 20133, Italy
| | - Valentina Ceserani
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Anna Ferri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Marta Dossena
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Pietro Mazzuca
- Department of Microbiology, Brescia University, Brescia, Italy
| | - Emilio Ciusani
- Laboratory of Clinical Pathology and Neurogenetic Medicine, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Piero Ceccarelli
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Arnaldo Caruso
- Department of Microbiology, Brescia University, Brescia, Italy
| | - Nazario Portolani
- Department of Medical and Surgical Sciences, University of Brescia, Brescia, Italy
| | - Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, Milan, 20133, Italy
| | - Eugenio Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| |
Collapse
|
34
|
Alessandri G, Leonetti C, Artuso S, Orlandi A, Passeri D, Benetti A, Berenzi A, Dessy E, Pascucci L, Ceccarelli P, Bonomi A, Coccè V, Portolani N, Ceserani V, Parati E, Pessina A. Abstract 4237: Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-4237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Mesenchymal stromal cells (MSCs) are considered an important therapeutic tool in cancer therapy. Because MSCs may home tumor microenvironment they have the possibility to directly delivery molecules to cancer cells. We have demonstrated that MSCs, upon in vitro priming with anti-cancer drug, become drug-releasing mesenchymal cells (Dr-MCs) able to strongly inhibit cancer cells growth. In order to expand our studies we here investigated whether intravenous (i.v) injection of MSCs loaded with Paclitaxel (PTX) were able to reduce B16 melanoma lung metastasis formation. To this end, as Dr-MCs, the murine MSC line SR4987 was used. SR4987 cells were loaded with PTX (SR4987PTX) by incubating for 24h with 2000ng/ml PTX. The anti-metastatic activity of SR4987PTX was evaluated in mice injected i.v. with 2.5 × 105 B16 melanoma cells. Tracking of the SR4987 in the lung was studied by immunohistochemistry using anti-Sca-1 antibodies. Adhesion and migration experiments were performed to elucidated the mechanism of SR4987PTX homing. In summary, we found that three i.v. injections of SR4987PTX on day 5, 10 and 15 after tumor injection almost completely (>90% inhibition) abolished B16 lung metastasis. This effect was significantly superior (p<0.01) than PTX given at the maximal tolerated dose of 10mg/Kg. SR4987PTX arrested into lung by interacting with endothelium and migrate toward cancer nodule through a complex mechanism involving primarily mouse lung stromal cells (mL-StCs). Indeed in vitro data show that mL-StCs treated with the conditioned medium (CM) of B16 cells (B16-CM) increase adhesion of SR4987PTX on lung endothelium (L-MECs) and stimulated their migration. In this contest the addition of the inflammatory cytokine TNFα enhanced both adhesion and migration of SR4987PTX. Additionally, we found that mL-StCs induce migration of SR4987PTX through the release SDF-1. Indeed, blocking SDF-1 activity by using anti-SDF-1 antibodies or its receptors CXCR4/CXCR7 with the compound AMD3100, migration of SR4987PTX was strongly reduced. In vivo SDF-1 expression was increased in mL-StCs surrounding metastases, while the presence of Sca-1+ cells nearby metastasis as well in the infiltrating microvessels confirmed the cancer homing capability of SR4987PTX. In conclusion, because it is known that cancer recruits circulating MSCs to form its stroma, it is proposed to exploit this property to fight it, by administrating exogenous MSCs carrying anticancer molecules. Our results show for the first time that Dr-MCs loaded with PTX are very effective as “Trojan horses” to delivery the drug and to strongly inhibit lung metastasis formation. Actually, a cure for lung metastasis in human is mostly unlikely, we think that our approach of using Dr-MCs loaded with PTX may represent a new valid and additive therapeutic tool to fight metastases and, perhaps, lung cancers in human.
Citation Format: Giulio Alessandri, Carlo Leonetti, Simona Artuso, Augusto Orlandi, Daniela Passeri, Anna Benetti, Angiola Berenzi, Enrico Dessy, Luisa Pascucci, Piero Ceccarelli, Arianna Bonomi, Valentina Coccè, Nazario Portolani, Valentina Ceserani, Eugenio Parati, Augusto Pessina. Drug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4237. doi:10.1158/1538-7445.AM2015-4237
Collapse
Affiliation(s)
| | | | - Simona Artuso
- 2Regina Elena National Cancer Institute,, Roma, Italy
| | | | | | - Anna Benetti
- 4Department of Pathology, Spedali Civili, and University of Brescia,, Brescia, Italy
| | - Angiola Berenzi
- 4Department of Pathology, Spedali Civili, and University of Brescia,, Brescia, Italy
| | - Enrico Dessy
- 4Department of Pathology, Spedali Civili, and University of Brescia,, Brescia, Italy
| | - Luisa Pascucci
- 5Section of Veterinary Anatomy, University of Perugia, Perugia, Italy
| | - Piero Ceccarelli
- 5Section of Veterinary Anatomy, University of Perugia, Perugia, Italy
| | - Arianna Bonomi
- 6Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Valentina Coccè
- 6Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Nazario Portolani
- 7Department of Medical and Surgical Sciences. University of Brescia,, Brescia, Italy
| | | | | | - Augusto Pessina
- 6Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| |
Collapse
|
35
|
Sisto F, Bonomi A, Cavicchini L, Coccè V, Scaltrito MM, Bondiolotti G, Alessandri G, Parati E, Pessina A. Human mesenchymal stromal cells can uptake and release ciprofloxacin, acquiring in vitro anti-bacterial activity. Cytotherapy 2014; 16:181-90. [PMID: 24438899 DOI: 10.1016/j.jcyt.2013.11.009] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2013] [Revised: 11/19/2013] [Accepted: 11/25/2013] [Indexed: 01/05/2023]
Abstract
BACKGROUND AIMS Traditional antibiotic therapy is based on the oral or systemic injection of antibiotics that are often unable to stop a deep infection (eg, osteomyelitis). We studied whether or not bone marrow stromal cells (BM-MSCs) are able to uptake and release ciprofloxacin (CPX), a fluoroquinolone considered the drug of choice for the treatment of chronic osteomyelitis because of its favorable penetration into poorly vascularized sites of infection. METHODS Human bone marrow stromal cells (BM-MSCs) were primed with CPX (BM-MSCsCPX) according to a methodology previously standardized in our laboratory for paclitaxel (PTX). The anti-microbial activity of CPX released from BM-MSCs cells (BM-MSCsCPX-CM) or supernatant from cell lysate (BM-MSCsCPX-LYS) was evaluated by agar dilution and microdilution methods on three bacterial strains (Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa). To investigate whether or not primed cells (BM-MSCsCPX) were able to directly act on the bacterial growth, co-colture was performed by mixing E. coli suspension to an increasing number of BM-MSCsCPX. The anti-bacterial activity was determined as number of BM-MSCsCPX that completely inhibited bacterial growth. RESULTS The results demonstrated that BM-MSCsCPX are able to uptake and then release CPX in the conditioned medium. The loaded antibiotic maintains its active form throughout the process as tested on bacteria. CONCLUSIONS Our findings suggest that CPX-loaded MSCs may represent an important device for carrying and delivering CPX (and perhaps other antibiotics) into infected deep microenvironments; they could be used for local application and by systemic infusion when their homing capacity into the bone is cleared.
Collapse
Affiliation(s)
- Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - Loredana Cavicchini
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | | | - Gianpietro Bondiolotti
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy
| | | | - Eugenio Parati
- Fondazione IRCCS, Neurological Institute Carlo Besta, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy.
| |
Collapse
|
36
|
Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, Viganò L, Locatelli A, Sisto F, Doglia SM, Parati E, Bernardo ME, Muraca M, Alessandri G, Bondiolotti G, Pessina A. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release 2014; 192:262-70. [PMID: 25084218 DOI: 10.1016/j.jconrel.2014.07.042] [Citation(s) in RCA: 597] [Impact Index Per Article: 59.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2014] [Revised: 07/14/2014] [Accepted: 07/20/2014] [Indexed: 12/13/2022]
Abstract
Mesenchymal stromal cells (MSCs) have been proposed for delivering anticancer agents because of their ability to home in on tumor microenvironment. We found that MSCs can acquire strong anti-tumor activity after priming with Paclitaxel (PTX) through their capacity to uptake and then release the drug. Because MSCs secrete a high amount of membrane microvesicles (MVs), we here investigated the role of MVs in the releasing mechanism of PTX. The murine SR4987 line was used as MSC model. The release of PTX from SR4987 in the conditioned medium (CM) was checked by HPLC and the anti-tumor activity of both CM and MVs was tested on the human pancreatic cell line CFPAC-1. MVs were isolated by ultracentrifugation, analyzed by transmission (TEM) and scanning electron microscopy (SEM), and the presence of PTX by the Fourier transformed infrared (FTIR) microspectroscopy. SR4987 loaded with PTX (SR4987PTX) secreted a significant amount of PTX and their CM possessed strong anti-proliferative activity on CFPAC-1. At TEM and SEM, SR4987PTX showed an increased number of "vacuole-like" structures and shed a relevant number of MVs, but did not differ from untreated SR4987. However, SR4987PTX-derived-MVs (SR4987PTX-MVs) demonstrated a strong anti proliferative activity on CFPAC-1. FTIR analysis of SR4987PTX-MVs showed the presence of an absorption spectrum in the corresponding regions of the PTX marker, absent in MVs from SR4987. Our work is the first demonstration that MSCs are able to package and deliver active drugs through their MVs, suggesting the possibility of using MSCs as a factory to develop drugs with a higher cell-target specificity.
Collapse
Affiliation(s)
- Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Diletta Ami
- Department of Biotechnology and Biosciences, University of Milan Bicocca, Milan, Italy
| | | | - Emilio Ciusani
- Laboratory of Clinical Pathology and Neurogenetic Medicine, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Lucia Viganò
- Department of Medical Oncology, Ospedale S. Raffaele Scientific Institute, Milan ,Italy
| | - Alberta Locatelli
- Department of Medical Oncology, Ospedale S. Raffaele Scientific Institute, Milan ,Italy
| | - Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | | | - Eugenio Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | | | - Maurizio Muraca
- Laboratory Medicine, Children's Hospital Bambino Gesù, Roma, Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases, IRCCS Neurological Institute C. Besta, Milan, Italy
| | - Gianpietro Bondiolotti
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
| |
Collapse
|
37
|
Balducci L, Blasi A, Saldarelli M, Soleti A, Pessina A, Bonomi A, Coccè V, Dossena M, Tosetti V, Ceserani V, Navone SE, Falchetti ML, Parati EA, Alessandri G. Immortalization of human adipose-derived stromal cells: production of cell lines with high growth rate, mesenchymal marker expression and capability to secrete high levels of angiogenic factors. Stem Cell Res Ther 2014; 5:63. [PMID: 24887516 PMCID: PMC4055112 DOI: 10.1186/scrt452] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2013] [Revised: 01/28/2014] [Accepted: 04/24/2014] [Indexed: 12/20/2022] Open
Abstract
INTRODUCTION Human adipose-derived stromal cells (hASCs), due to their relative feasibility of isolation and ability to secrete large amounts of angiogenic factors, are being evaluated for regenerative medicine. However, their limited culture life span may represent an obstacle for both preclinical investigation and therapeutic use. To overcome this problem, hASCs immortalization was performed in order to obtain cells with in vitro prolonged life span but still maintain their mesenchymal marker expression and ability to secrete angiogenic factors. METHODS hASCs were transduced with the human telomerase reverse transcriptase (hTERT) gene alone or in combination with either SV-40 or HPV E6/E7 genes. Mesenchymal marker expression on immortalized hASCs lines was confirmed by flow cytometry (FC), differentiation potential was evaluated by immunocytochemistry and ELISA kits were used for evaluation of angiogenic factors. Green fluorescent protein (GFP) gene transduction was used to obtain fluorescent cells. RESULTS We found that hTERT alone failed to immortalize hASCs (hASCs-T), while hTERT/SV40 (hASCs-TS) or hTERT/HPV E6/E7 (hASCs-TE) co-transductions successfully immortalized cells. Both hASCs-TS and hASCs-TE were cultured for up to one year with a population doubling level (PDL) up to 100. Comparative studies between parental not transduced (hASCs-M) and immortalized cell lines showed that both hASCs-TS and hASCs-TE maintained a mesenchymal phenotypic profile, whereas differentiation properties were reduced particularly in hASCs-TS. Interestingly, hASCs-TS and hASCs-TE showed a capability to secrete significant amount of HGF and VEGF. Furthermore, hASCs-TS and hASCs-TE did not show tumorigenic properties in vitro although some chromosomal aberrations were detected. Finally, hASCs-TS and hASCs-TE lines were stably fluorescent upon transduction with the GFP gene. CONCLUSIONS Here we demonstrated, for the first time, that hASCs, upon immortalization, maintain a strong capacity to secrete potent angiogenic molecules. By combining hASCs immortalization and their paracrine characteristics, we have developed a "hybridoma-like model" of hASCs that could have potential applications for discovering and producing molecules to use in regenerative medicine (process scale-up).
Collapse
Affiliation(s)
- Luigi Balducci
- Medestea Research and Production Laboratories, Consorzio CARSO, Bari, Italy
| | - Antonella Blasi
- Medestea Research and Production Laboratories, Consorzio CARSO, Bari, Italy
| | | | - Antonio Soleti
- Medestea Research and Production Laboratories, Consorzio CARSO, Bari, Italy
| | - Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
| | - Marta Dossena
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Valentina Tosetti
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Valentina Ceserani
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Stefania Elena Navone
- Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, Italy
| | | | - Eugenio Agostino Parati
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - Giulio Alessandri
- Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| |
Collapse
|
38
|
Duchi S, Dambruoso P, Martella E, Sotgiu G, Guerrini A, Lucarelli E, Pessina A, Coccè V, Bonomi A, Varchi G. Thiophene-based compounds as fluorescent tags to study mesenchymal stem cell uptake and release of taxanes. Bioconjug Chem 2014; 25:649-55. [PMID: 24628247 DOI: 10.1021/bc5000498] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Human mesenchymal stem cells (hMSC) are multipotent cells that display the unique ability to home and engraft in tumor stroma. This remarkable tumor tropic property has generated a great deal of interest in many clinical settings. Recently, we showed that hMSC represent an excellent base for cell-mediated anticancer therapy since they are able to internalize paclitaxel (PTX) and to release it in an amount sufficient to inhibit tumor cell proliferation. In order to shed light on the dynamics of drug uptake and release, in the present paper we describe the synthesis of two novel thiophene-based fluorophore-paclitaxel conjugates, namely PTX-F32 and PTX-F35, as tools for in vitro drug tracking. We aimed to study the ability of these novel derivatives to be efficiently internalized by hMSC and, in a properly engineered coculture assay, to be released in the medium and taken up by tumor cells. In order to ensure better stability of the conjugates toward enzymatic hydrolysis, the selected oligothiophenes were connected to the taxol core at the C7 position through a carbamate linkage between PTX and the diamino linker. Antiproliferative experiments on both tumor cells and stromal cells clearly indicate that, in good correlation with the parent compound, cells are sensitive to nanomolar concentrations of the fluorescent conjugates. Moreover, in the coculture assay we were able to monitor, by fluorescence microscopy, PTX-F32 trafficking from hMSC toward glioblastoma U87 tumor cells. Our work paves the way for novel possibilities to perform extensive and high quality fluorescence-based analysis in order to better understand the cellular mechanisms involved in drug trafficking, such as microvescicle/exosome mediated release, in hMSC vehicle cells.
Collapse
Affiliation(s)
- S Duchi
- Osteoarticular Regeneration Laboratory, Rizzoli Orthopaedic Institute , 40136 Bologna, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Navone SE, Pascucci L, Dossena M, Ferri A, Invernici G, Acerbi F, Cristini S, Bedini G, Tosetti V, Ceserani V, Bonomi A, Pessina A, Freddi G, Alessandrino A, Ceccarelli P, Campanella R, Marfia G, Alessandri G, Parati EA. Decellularized silk fibroin scaffold primed with adipose mesenchymal stromal cells improves wound healing in diabetic mice. Stem Cell Res Ther 2014; 5:7. [PMID: 24423450 PMCID: PMC4055150 DOI: 10.1186/scrt396] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2013] [Revised: 10/21/2013] [Accepted: 01/06/2014] [Indexed: 01/13/2023] Open
Abstract
INTRODUCTION Silk fibroin (SF) scaffolds have been shown to be a suitable substrate for tissue engineering and to improve tissue regeneration when cellularized with mesenchymal stromal cells (MSCs). We here demonstrate, for the first time, that electrospun nanofibrous SF patches cellularized with human adipose-derived MSCs (Ad-MSCs-SF), or decellularized (D-Ad-MSCs-SF), are effective in the treatment of skin wounds, improving skin regeneration in db/db diabetic mice. METHODS The conformational and structural analyses of SF and D-Ad-MSCs-SF patches were performed by scanning electron microscopy, confocal microscopy, Fourier transform infrared spectroscopy and differential scanning calorimetry. Wounds were performed by a 5 mm punch biopsy tool on the mouse's back. Ad-MSCs-SF and D-Ad-MSCs-SF patches were transplanted and the efficacy of treatments was assessed by measuring the wound closure area, by histological examination and by gene expression profile. We further investigated the in vitro angiogenic properties of Ad-MSCs-SF and D-Ad-MSCs-SF patches by affecting migration of human umbilical vein endothelial cells (HUVECs), keratinocytes (KCs) and dermal fibroblasts (DFs), through the aortic ring assay and, finally, by evaluating the release of angiogenic factors. RESULTS We found that Ad-MSCs adhere and grow on SF, maintaining their phenotypic mesenchymal profile and differentiation capacity. Conformational and structural analyses on SF and D-Ad-MSCs-SF samples, showed that sterilization, decellularization, freezing and storing did not affect the SF structure. When grafted in wounds of diabetic mice, both Ad-MSCs-SF and D-Ad-MSCs-SF significantly improved tissue regeneration, reducing the wound area respectively by 40% and 35%, within three days, completing the process in around 10 days compared to 15-17 days of controls. RT2 gene profile analysis of the wounds treated with Ad-MSCs-SF and D-Ad-MSCs-SF showed an increment of genes involved in angiogenesis and matrix remodeling. Finally, Ad-MSCs-SF and D-Ad-MSCs-SF co-cultured with HUVECs, DFs and KCs, preferentially enhanced the HUVECs' migration and the release of angiogenic factors stimulating microvessel outgrowth in the aortic ring assay. CONCLUSIONS Our results highlight for the first time that D-Ad-MSCs-SF patches are almost as effective as Ad-MSCs-SF patches in the treatment of diabetic wounds, acting through a complex mechanism that involves stimulation of angiogenesis. Our data suggest a potential use of D-Ad-MSCs-SF patches in chronic diabetic ulcers in humans.
Collapse
Affiliation(s)
- Stefania Elena Navone
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
- Current address: Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, via Francesco Sforza, 28 20122 Milan, Italy
| | - Luisa Pascucci
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | - Marta Dossena
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Anna Ferri
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Gloria Invernici
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Francesco Acerbi
- Neurosurgery Department, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Silvia Cristini
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Gloria Bedini
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Valentina Tosetti
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Valentina Ceserani
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Arianna Bonomi
- Department of Public Health, Microbiology, Virology, University of Milan, Milan, Italy
| | - Augusto Pessina
- Department of Public Health, Microbiology, Virology, University of Milan, Milan, Italy
| | - Giuliano Freddi
- Innovhub-SSI, Div. Stazione Sperimentale per la Seta, Milan, Italy
| | | | - Piero Ceccarelli
- Department of Veterinary Medicine, University of Perugia, Perugia, Italy
| | | | - Giovanni Marfia
- Laboratory of Experimental Neurosurgery and Cell Therapy, Neurosurgery Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milano, Milan, Italy
| | - Giulio Alessandri
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| | - Eugenio Agostino Parati
- The Cellular Neurobiology Laboratory, Cerebrovascular Diseases Unit, IRCCS Foundation Neurological Institute “C. Besta”, Milan, Italy
| |
Collapse
|
40
|
Pellai A, Festa F, Cilento F, Grossi L, Grassino E, Zaffaroni M, Guidi C, Bona G, Bonomi A, Visentin R, Angellotti P, Guala A. [What new fathers know, think and do: a survey about fathering's attitudes, beliefs and behaviors in a sample of 570 men just after the birth of their newborn]. Minerva Pediatr 2013; 65:531-540. [PMID: 24056379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
AIM The aim of this paper was to know and analyze information, attitudes and behaviors related with transformations occurring in men when they become fathers. METHODS A self-administered questionnaire has been given out to all men whose newborns were born in the Hospitals located into Borgosesia, Ivrea, Novara, Verbania and Vercelli (Piedmont region in north west of the Italy) in the last quarter of 2006. The questionnaire was created ad hoc and filled out on the day of discharge; results underwent statistical analyses through SPSS system. RESULTS For the duration of the research, out of 870 men who became fathers in the hospitals were involved in this study, 570 responded voluntarily to the self-administered questionnaire (65.6% of the total sample). They showed a lack of information about how to take care of their newborns and the emotional turmoil of women after delivery (58% think children are blind when they are born, 52% think it is better to breastfeed newborns at fixed times and 47% ignore that mothers can enter a depression state). Eighty-eight percent of respondents were in the delivery room to see their child's birth, 56% took a leave from job to stay with mother and child in the hospital and 58% of them report the intention to take an additional 2-3 days leave after coming home from the hospital; 27% had trouble sleeping during pregnancy and are afraid not to be good fathers for their child; 90% believe that their newborn will make them change life habits. Most of the new fathers had difficulties in sharing emotions and feelings related with their status of fathers-to-be with other men. Some of these results are significantly different in older fathers, fathers having their first child and fathers with a lesser level of education. CONCLUSION During pregnancy and in the first months after their child is born, fathers-to-be and new fathers must be considered a potential target for educational interventions aiming at promoting their parenting information and reinforcing their positive attitudes and beliefs related with their fathering status.
Collapse
Affiliation(s)
- A Pellai
- Dipartimento di Sanità Pubblica, Università di Milano, Milano, Italia -
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Abstract
To study hematotoxicity of compounds on the myeloid cell compartment, the authors describe a standard procedure developed as a workable good laboratory practices-compliant protocol to determine the in vitro myelotoxic effect of drugs and chemicals. Specific protocols are presented to prepare human and murine myeloid progenitors (CFU-GM) for testing in a validated CFU-GM assay. Details are given for performing a screening test when toxicity data are not available and for passing on to an accurate inhibitory concentration-determination phase. To quantify the potential hematotoxicity of xenobiotics from their direct adverse effects on CFU-GM, the unit describes how to manage the results by means of an algorithm able to predict the acute xenobiotic exposure levels that cause maximum tolerated decreases (MTD) in absolute neutrophil count (ANC). A protocol describes a miniaturized application of the procedure in 96-well plates for high-throughput screening of compounds or for testing compounds that are available in very small quantities.
Collapse
|
42
|
Pessina A, Coccè V, Bonomi A, Cavicchini L, Sisto F, Ferrari M, Ciusani E, Navone S, Marfia G, Parati E, Alessandri G. Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel. Anticancer Agents Med Chem 2013; 13:523-530. [PMID: 22931415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 07/05/2012] [Accepted: 07/10/2012] [Indexed: 06/01/2023]
Abstract
The main goal in cancer chemotherapy is to drive the drug into the tumor microenvironment to kill as many cancer cells as possible while producing the lowest collateral toxicity. Previously, we have shown that human bone marrow derived mesenchymal stromal cells (hBM-MSCs) exposed to Paclitaxel (PTX) were able to uptake and subsequently release the drug in the culture medium. PTX primed hBM-MSCs (hBM-MSCsPTX) located in the vicinity of cancer cells produced a strong inhibition of tumor cell growth both in vitro and in vivo. To expand these observations, in the present study we exposed human skin derived fibroblasts (hSDFs) to 2,000 ng/ml of PTX and then tested both cells and their conditioned medium (CM) in vitro for their capacity to inhibit the proliferation of human tumor cell lines (MOLT-4, DU-145, U87-MG, SH-SY5Y(+) and LAN-5). We found that hSDFs primed with PTX (hSDFsPTX) were able to uptake and subsequently release PTX in a time dependent manner. hSDFsPTX-derived CM(hSDFsPTX-CM) from 1:4 to 1:10 dilutions produced a significant (p < 0.05) in vitro tumor growth inhibition. hSDFsPTX co-cultured with leukemia cells at 1:1 to 1:10 ratio, completely inhibited cells growth whereas no inhibition was induced by normal hSDFs cells. Our results demonstrate for the first time that hSDFs can be loaded in vitro with PTX and thus can acquire a potent anti-tumor activity. Since hSDFs can be easily isolated from skin biopsies without any particular pain and discomfort to donor patients, we conclude that hSDFs may represent a valid cell type option for carrying and delivering anti-cancer drugs.
Collapse
Affiliation(s)
- Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133 Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Pessina A, Cocce V, Bonomi A, Cavicchini L, Sisto F, Ferrari M, Ciusani E, Navone S, Marfia G, Parati E, Alessandri G. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel. Anticancer Agents Med Chem 2013. [DOI: 10.2174/187152013804910415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
44
|
Pessina A, Coccè V, Pascucci L, Bonomi A, Cavicchini L, Sisto F, Ferrari M, Ciusani E, Crovace A, Falchetti ML, Zicari S, Caruso A, Navone S, Marfia G, Benetti A, Ceccarelli P, Parati E, Alessandri G. Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice. Br J Haematol 2013; 160:766-78. [DOI: 10.1111/bjh.12196] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2012] [Accepted: 11/19/2012] [Indexed: 01/14/2023]
Affiliation(s)
- Augusto Pessina
- Department of Biomedical, Surgical and Dental Sciences; University of Milan; Milan Italy
| | - Valentina Coccè
- Department of Biomedical, Surgical and Dental Sciences; University of Milan; Milan Italy
| | - Luisa Pascucci
- Section of Veterinary Anatomy; Department of Biopathological Sciences and Hygiene of Animal and Food Productions; University of Perugia; Milan Italy
| | - Arianna Bonomi
- Department of Biomedical, Surgical and Dental Sciences; University of Milan; Milan Italy
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| | - Loredana Cavicchini
- Department of Biomedical, Surgical and Dental Sciences; University of Milan; Milan Italy
| | - Francesca Sisto
- Department of Biomedical, Surgical and Dental Sciences; University of Milan; Milan Italy
| | - Maura Ferrari
- Istituto Zooprofilattico Sperimentale della Lombardia e dell'Emilia Romagna; Brescia Italy
| | - Emilio Ciusani
- Laboratory of Clinical Pathology and Neurogenetic Medicine; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| | - Antonio Crovace
- Dipartimento dell'Emergenza e dei Trapianti di Organi (D.E.T.O.), Sezione di Chirurgia Veterinaria; Università degli Studi di Bari Aldo Moro; Bari Italy
| | | | - Sonia Zicari
- Department of Microbiology; University of Brescia and Spedali Civili; Brescia Italy
| | - Arnaldo Caruso
- Department of Microbiology; University of Brescia and Spedali Civili; Brescia Italy
| | - Stefania Navone
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| | - Giovanni Marfia
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| | - Anna Benetti
- 2nd Department of Pathology; University of Brescia and Spedali Civili; Brescia Italy
| | - Piero Ceccarelli
- Section of Veterinary Anatomy; Department of Biopathological Sciences and Hygiene of Animal and Food Productions; University of Perugia; Milan Italy
| | - Eugenio Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| | - Giulio Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Neurological Institute Carlo Besta; Milan Italy
| |
Collapse
|
45
|
Bonomi A, Coccè V, Cavicchini L, Sisto F, Dossena M, Balzarini P, Portolani N, Ciusani E, Parati E, Alessandri G, Pessina A. Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity. Int J Immunopathol Pharmacol 2013; 26:33-41. [DOI: 10.1177/03946320130260s105] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Affiliation(s)
- A. Bonomi
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - V. Coccè
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - L. Cavicchini
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - F. Sisto
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| | - M. Dossena
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - P. Balzarini
- Second Department of Pathology, University of Brescia and Spedali Civili, Brescia, Italy
| | - N. Portolani
- Second Department of Pathology, University of Brescia and Spedali Civili, Brescia, Italy
| | - E. Ciusani
- Department of Diagnostics and Applied Technology, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy
| | - E. Parati
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - G. Alessandri
- Cellular Neurobiology Laboratory, Department of Cerebrovascular Diseases; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - A. Pessina
- Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy
| |
Collapse
|
46
|
Pessina A, Cocce V, Bonomi A, Cavicchini L, Sisto F, Ferrari M, Ciusani E, Navone S, Marfia G, Parati E, Alessandri G. Human Skin-Derived Fibroblasts Acquire In Vitro Anti-Tumor Potential after Priming with Paclitaxel. Anticancer Agents Med Chem 2013. [DOI: 10.2174/1871520611313030015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
47
|
Pessina A, Bonomi A, Coccè V, Invernici G, Navone S, Cavicchini L, Sisto F, Ferrari M, Viganò L, Locatelli A, Ciusani E, Cappelletti G, Cartelli D, Arnaldo C, Parati E, Marfia G, Pallini R, Falchetti ML, Alessandri G. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. PLoS One 2011; 6:e28321. [PMID: 22205945 PMCID: PMC3243689 DOI: 10.1371/journal.pone.0028321] [Citation(s) in RCA: 123] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2011] [Accepted: 11/05/2011] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Mesenchymal stromal cells may represent an ideal candidate to deliver anti-cancer drugs. In a previous study, we demonstrated that exposure of mouse bone marrow derived stromal cells to Doxorubicin led them to acquire anti-proliferative potential towards co-cultured haematopoietic stem cells (HSCs). We thus hypothesized whether freshly isolated human bone marrow Mesenchymal stem cells (hMSCs) and mature murine stromal cells (SR4987 line) primed in vitro with anti-cancer drugs and then localized near cancer cells, could inhibit proliferation. METHODS AND PRINCIPAL FINDINGS Paclitaxel (PTX) was used to prime culture of hMSCs and SR4987. Incorporation of PTX into hMSCs was studied by using FICT-labelled-PTX and analyzed by FACS and confocal microscopy. Release of PTX in culture medium by PTX primed hMSCs (hMSCsPTX) was investigated by HPLC. Culture of Endothelial cells (ECs) and aorta ring assay were used to test the anti-angiogenic activity of hMSCsPTX and PTX primed SR4987(SR4987PTX), while anti-tumor activity was tested in vitro on the proliferation of different tumor cell lines and in vivo by co-transplanting hMSCsPTX and SR4987PTX with cancer cells in mice. Nevertheless, despite a loss of cells due to chemo-induced apoptosis, both hMSCs and SR4987 were able to rapidly incorporate PTX and could slowly release PTX in the culture medium in a time dependent manner. PTX primed cells acquired a potent anti-tumor and anti-angiogenic activity in vitro that was dose dependent, and demonstrable by using their conditioned medium or by co-culture assay. Finally, hMSCsPTX and SR4987PTX co-injected with human cancer cells (DU145 and U87MG) and mouse melanoma cells (B16) in immunodeficient and in syngenic mice significantly delayed tumor takes and reduced tumor growth. CONCLUSIONS These data demonstrate, for the first time, that without any genetic manipulation, mesenchymal stromal cells can uptake and subsequently slowly release PTX. This may lead to potential new tools to increase efficacy of cancer therapy.
Collapse
Affiliation(s)
- Augusto Pessina
- Department of Public Health, Microbiology, Virology, University of Milan, Milan, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Sisto F, Scaltrito MM, Zago M, Bonomi A, Coccè V, Frugoni S. Molecular analysis of relapses or reinfections of Clostridium difficile-associated diarrhea. New Microbiol 2011; 34:399-402. [PMID: 22143813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 05/05/2011] [Indexed: 05/31/2023]
Abstract
Recurrence is a major complication of Clostridium difficile-associated diarrhea and occurs in 15 to 20% of patients after discontinuation of therapy. Strains from 53 patients with Clostridium difficile recurrences were fingerprinted by PCR ribotyping. Reinfection with a different strain occurred in 15 out of 53 patients (28,3%), while 38 patients relapsed. These data suggest the need to perform molecular typing for implementation of infection control procedures and for a more appropriate therapeutic strategy.
Collapse
Affiliation(s)
- Francesca Sisto
- Dipartimento di Sanità Pubblica-Microbiologia-Virologia, Università degli Studi, Milano, Italy.
| | | | | | | | | | | |
Collapse
|
49
|
Alessandri G, Bonomi A, Coccè V, Cavicchini L, Invernici G, Cristini S, Sisto F, Ferrari M, Ciusani E, Cappelletti G, Cartelli D, Parati E, Pessina A. Abstract 4354: Mesenchymal stem cells loaded with paclitaxel inhibit tumor growth and angiogenesis. Cancer Res 2011. [DOI: 10.1158/1538-7445.am2011-4354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Mesenchymal stem cells (MSCs) may represent an ideal candidate to deliver anti-cancer drugs. In a previous study, we demonstrated that simple exposure of bone marrow (BM) derived MSCs to high doses of Doxorubicin, led them to acquire anti-proliferative potential towards co-cultured haematopoitic stem cells (HSCs). We thus hypothesized whether MSCs, once primed in vitro with anti-cancer drugs and then localized near cancer cells, can inhibit proliferation. Methods: Paclitaxel (PTX) was used to prime culture of mouse and human MSCs. Incorporation of PTX into MSCs (MSCsPTX) was studied by using FICT-labelled-PTX and analyzed by FACS and confocal microscopy. Release of PTX in culture medium by MSCsPTX was investigated by HPLC. Culture of Endothelial cells (ECs) and aorta ring assay were used to test the anti-angiogenic activity of MSCsPTX, while anti-tumor activity was tested in vitro on the proliferation of different tumor cell lines and in vivo by co-transplanting MSCsPTX with cancer cells in mice.
Results: MSCs were able to rapidly incorporate PTX and could slowly release PTX in the culture medium in a time dependent manner. Primed MSCsPTX acquired a potent anti-tumor and anti-angiogenic activity in vitro that was dose dependent, and demonstrable by using their conditioned medium or by co-culture assay. Finally, MSCsPTX co-injected in immunodeficient mice with DU145 and B16 cancer cells, significantly delayed tumor takes and reduced tumor growth.
Conclusions: These data demonstrate that, without any genetic manipulation, MSCs can uptake and subsequently slowly release PTX, becoming a potential new tool for cancer therapy.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4354. doi:10.1158/1538-7445.AM2011-4354
Collapse
Affiliation(s)
| | - Arianna Bonomi
- 2Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy
| | - Valentina Coccè
- 2Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy
| | - Loredana Cavicchini
- 2Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy
| | | | | | - Francesca Sisto
- 2Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy
| | - Maura Ferrari
- 4Istituto Zooprofilattico Sperimentale della Lombardia e dell’ Emilia Romagna, Brescia, Italy
| | | | | | | | | | - Augusto Pessina
- 2Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy
| |
Collapse
|
50
|
Pessina A, Sisto F, Coccè V, Cavicchini L, Ciusani E, Gribaldo L, Bonomi A. A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into osteoblast-like cells. Cell Biol Toxicol 2010; 27:169-80. [DOI: 10.1007/s10565-010-9179-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2010] [Accepted: 12/09/2010] [Indexed: 11/28/2022]
|